<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2110200234
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Kymriah
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TISAGENLECLEUCEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        cells
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Dispersion for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store at temperatures below -140°C in the vapour phase of liquid nitrogen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1633500
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>Kymriah is</strong></p><p>Kymriah, also known as tisagenlecleucel, is made from some of your own white blood cells called T cells. T cells are important for your immune system (the body&rsquo;s defences) to work properly.</p><p>&nbsp;</p><p><strong>How does Kymriah work?</strong></p><p>The T cells are taken from your blood and a new gene is put into the T cells so that they can target the cancer cells in your body. When Kymriah is infused into your blood, the modified T cells will find and kill the cancer cells.</p><p>&nbsp;</p><p><strong>What Kymriah is used for</strong></p><p>Kymriah is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>B‑cell acute lymphoblastic leukaemia (B‑cell ALL)</strong> ‑ a form of cancer that affects some other types of white blood cells. The medicine can be used in children and young adults up to and including 25&nbsp;years of age with this cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Diffuse</strong><strong> large B‑cell lymphoma (DLBCL)</strong> ‑ a form of cancer that affects some types of white blood cells, mostly in the lymph nodes. The medicine can be used in adults (18&nbsp;years of age or older) with this cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Follicular lymphoma (FL)</strong> - a form of cancer that affects some types of white blood cells, called lymphocytes, mostly in the lymph nodes. The medicine can be used in adults (18&nbsp;years of age or older) with this cancer.</p><p>&nbsp;</p><p>If you have any questions about how Kymriah works or why this medicine has been prescribed for you, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.You should not be given Kymriah:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to any of the ingredients of this medicine (listed in section&nbsp;6). If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>b.Take a special care with Kymriah</strong></p><p>Kymriah is made from your own white blood cells and should only be given to you.</p><p>Patients treated with Kymriah may develop new types of cancers. There have been reports of patients developing cancer, beginning in a type of white blood cells called T-cells, after treatment with Kymriah and similar medicines. Talk to your doctor if you experience any new swelling of your glands (lymph nodes) or changes in your skin such as new rashes or lumps.</p><p>&nbsp;</p><p><strong>Before you are given Kymriah you should tell your doctor if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had a stem cell transplant in the last 4&nbsp;months. Your doctor will check if you have signs or symptoms of graft‑versus‑host disease. This happens when transplanted cells attack your body, causing symptoms such as rash, nausea, vomiting, diarrhoea and bloody stools.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have any lung, heart or blood pressure (low or raised) problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You notice the symptoms of your cancer are getting worse. If you have leukaemia this might include fever, feeling weak, bleeding gums, bruising. If you have lymphoma, this might include unexplained fever, feeling weak, night sweats, sudden weight loss.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have an infection. The infection will be treated before the Kymriah infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are pregnant, think you may be pregnant, or plan to become pregnant (see sections &ldquo;Pregnancy and breast‑feeding&rdquo; and &ldquo;Contraception for women and men&rdquo; below).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You had a vaccination in the previous 6&nbsp;weeks or are planning to have one in the next few months.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before being given Kymriah.</p><p>&nbsp;</p><p><strong>Test and checks</strong></p><p><strong>Before you are given Kymriah</strong> <strong>your doctor will:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check your lungs, heart and blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look for signs of infection; any infection will be treated before you are given Kymriah.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check if your lymphoma or leukaemia is getting worse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look for signs of graft‑versus‑host disease that can happen after a transplant.</p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>Check your blood for uric acid and for how many cancer cells there are in your blood. This will show if you are likely to develop a condition called tumour lysis syndrome. You may be given medicines to help prevent the condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check for hepatitis B, hepatitis C or HIV infection.</p><p>&nbsp;</p><p><strong>After you have been given Kymriah</strong></p><p><strong>Tell your doctor or nurse immediately if you have any of the following:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, which may be a symptom of an infection. Your doctor will regularly check your blood counts as the number of blood cells and other blood components may decrease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take your temperature twice a day for 3‑4&nbsp;weeks after treatment with Kymriah. If your temperature is high, see your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extreme tiredness, weakness and shortness of breath, which may be symptoms of a lack of red blood cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding or bruising more easily, which may be symptoms of low levels of cells in the blood known as platelets.</p><p>&nbsp;</p><p>There may be an effect on the results of some types of HIV test &ndash; ask your doctor about this.</p><p>&nbsp;</p><p>Your doctor will regularly monitor your blood counts after you receive Kymriah as you may experience a reduction in the number of blood cells and other blood components.</p><p>&nbsp;</p><p>Do not donate blood, organs, tissues or cells.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No formal studies have been performed in paediatric patients below 3&nbsp;years of age in B‑cell ALL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kymriah should not be used in children and adolescents below 18&nbsp;years of age to treat DLBCL and FL. This is because Kymriah has not been studied in this age group.</p><p>&nbsp;</p><p><strong>c.Taking or using other medicines and Kymriah</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. This is because other medicines can affect the way Kymriah works.</p><p>&nbsp;</p><p>In particular, you must not be given certain vaccines called live vaccines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the 6&nbsp;weeks before you are given the short course of chemotherapy (called lymphodepleting chemotherapy) to prepare your body for the Kymriah cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during Kymriah treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after treatment while the immune system is recovering.</p><p>Talk to your doctor if you need to have any vaccinations.</p><p>&nbsp;</p><p>Before you are given Kymriah tell your doctor or nurse if you are taking any medicines that weaken your immune system such as corticosteroids, since these medicines may interfere with the effect of Kymriah.</p><p>&nbsp;</p><p><strong>d.Pregnancy and breast‑feeding</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine. This is because the effects of Kymriah in pregnant or breast‑feeding women are not known, and it may harm your unborn baby or your newborn/infant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you become pregnant or think you may be pregnant after treatment with Kymriah, talk your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be given a pregnancy test before treatment starts. Kymriah should only be given if the result shows you are not pregnant.</p><p>&nbsp;</p><p><strong>Contraception for women and men</strong></p><p>Discuss pregnancy with your doctor if you have received Kymriah.</p><p>&nbsp;</p><p><strong>e.Driving and using machines</strong></p><p>Do not drive, use machines, or take part in activities that need you to be alert for. Kymriah can cause problems such as altered or decreased consciousness, confusion and seizures (fits) in the 8&nbsp;weeks following infusion.</p><p><strong>&nbsp;</strong></p><p><strong>f. Important information about some of the ingredients of Kymriah</strong></p><p><strong>Kymriah contains sodium, dimethylsulfoxide (DMSO) and dextran 40.</strong></p><p>This medicine contains 24.3 to 121.5&nbsp;mg sodium per dose. This is equivalent to 1 to 6% of the recommended maximum daily dietary intake of 2&nbsp;g sodium for an adult. You should be observed closely during the infusion period.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How Kymriah is given</strong></p><p>&nbsp;</p><p>Kymriah will always be given to you by a doctor in a qualified treatment centre.</p><p>&nbsp;</p><p>Kymriah contains human blood cells. Your doctor handling Kymriah will therefore take appropriate precautions (wearing gloves and glasses) to avoid potential transmission of infectious diseases.</p><p>&nbsp;</p><p><strong>Giving blood to make Kymriah</strong></p><p>Kymriah is made from your own white blood cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will take some of your blood using a catheter placed in your vein (a procedure called leukapheresis). Some of your white blood cells are separated from your blood and the rest of your blood is returned to your vein. This can take 3 to 6&nbsp;hours and may need to be repeated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your white blood cells are frozen and sent away to make Kymriah. It usually takes about 3 to 4&nbsp;weeks to make Kymriah but the time may vary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kymriah is a treatment that is manufactured specifically for you. There are situations where Kymriah cannot be successfully manufactured and be given to you. In some cases, a second manufacturing of Kymriah may be attempted.</p><p>Before you are given Kymriah, your doctor may give you a type of treatment called lymphodepleting chemotherapy for a few days to prepare your body.</p><p>&nbsp;</p><p><strong>Cancer treatment while Kymriah is being made</strong></p><p>During the period while Kymriah is being made, your lymphoma or leukaemia may get worse and your doctor may decide to use an additional treatment (known as &ldquo;bridging therapy&rdquo;) to stabilise your cancer by stopping new cancer cells from developing. This treatment may lead to side effects and these may be severe or life-threatening. Your doctor will inform you of the potential side effects of this treatment.</p><p>&nbsp;</p><p><strong>Medicines given immediately before Kymriah treatment</strong></p><p>During the 30 to 60&nbsp;minutes before you are given Kymriah you may be given other medicines. This is to help prevent infusion reactions and fever. These other medicines may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paracetamol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An antihistamine such as diphenhydramine.</p><p>&nbsp;</p><p><strong>How you are given Kymriah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will check that the individual patient identifiers on the Kymriah infusion bag match up to you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will give you Kymriah by infusion, which means it will be given as a drip through a tube in your vein. This usually takes less than 1&nbsp;hour. During the infusion your doctor will check if you have difficulty breathing or dizziness (possible symptoms of an allergic reaction).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kymriah is a one‑time treatment.</p><p>&nbsp;</p><p><strong>After you are given Kymriah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plan to stay within 2&nbsp;hours&rsquo; travel from the hospital where you were treated for at least 4&nbsp;weeks after you have been given Kymriah. Your doctor will recommend that you return to the hospital daily for at least 10&nbsp;days and will consider whether you need to stay at the hospital as an in‑patient for the first 10&nbsp;days after infusion. This is so your doctor can check if your treatment is working and help you if you have any side effects.</p><p>&nbsp;</p><p>If you miss an appointment, call your doctor or the hospital as soon as possible to reschedule.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong> if you get any of the following side effects after the Kymriah infusion. They usually happen in the first 8&nbsp;weeks after the infusion, but can also develop later:</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10&nbsp;people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high fever and chills. These may be symptoms of a serious condition called cytokine release syndrome which may be life-threatening or fatal. Other symptoms of cytokine release syndrome are difficulty breathing, nausea, vomiting, diarrhoea, loss of appetite, fatigue, muscle pain, joint pain, swelling, low blood pressure, fast heartbeat, headache, heart, lung and kidney failure and liver injury. These symptoms almost always occur within the first14&nbsp;days after infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems such as altered thinking or decreased consciousness, loss of contact with reality, confusion, agitation, seizures, difficulty speaking and understanding speech, difficulty walking. These may be symptoms of a condition called immune effector cell-associated neurotoxicity syndrome (ICANS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling warm, fever, chills or shivering, sore throat or mouth ulcers may be signs of an infection. Some infections may be life-threatening or fatal.</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10&nbsp;people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid breakdown of tumour cells causing release of their contents into the bloodstream. This can interfere with the workings of various body organs, especially the kidneys, heart and nervous system (tumour lysis syndrome).</p><p>&nbsp;</p><p><strong>Other possible side effects</strong></p><p>Other side effects are listed below. If these side effects become severe or serious, tell your doctor immediately.</p><p>&nbsp;</p><p><strong>Very common:</strong> <em>may affect more than 1 in 10&nbsp;people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pale skin, weakness, breathlessness due to low number of red blood cells or low haemoglobin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive or prolonged bleeding or bruising due to low number of platelets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever with dangerously low white blood cell count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased risk of infection due to abnormally low number of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequent and persistent infections due to decreased antibodies in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness, abnormal heart rhythms, due to abnormally low level of blood salts including phosphorus, potassium, magnesium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High levels of liver enzymes or creatinine in the blood that show that your liver or kidneys are not working normally</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast or irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, laboured breathing, rapid breathing, fluid in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone and back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen ankles, limbs and face</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Common:</strong> <em>may affect up to 1 in 10&nbsp;people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, malaise, enlarged liver, yellow colour of your skin and eyes, low blood cell counts due to severe immune activation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness or fainting, flushing, rash, itching, fever, shortness of breath or vomiting, abdominal pain, diarrhoea due to infusion related reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, nausea, vomiting, diarrhoea including bloody stools (possible symptoms of graft-versus-host disease which is when transplanted cells attack your cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the joints due to high level of uric acid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal blood test results (high level of: phosphorus, potassium, calcium, magnesium and sodium, an enzyme called alkaline phosphatase to help detect liver disease, fibrin d-dimer, serum ferritin; low level of: blood protein called albumin, sodium)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion, fits (seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms/cramping due to abnormally low level of blood salts including calcium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Involuntary or uncontrollable movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Involuntary shaking of the body, difficulty writing, difficulty expressing thoughts verbally, impaired attention, sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or numbness, difficulty moving because of nerve damage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nerve pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe state of confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathlessness, difficulty breathing when lying down, swelling of the feet or legs (possible symptoms of heart failure), stopped heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling and pain due to blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling due to fluids leaking from blood vessels into the surrounding tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bloating and discomfort (abdominal distension), due to an accumulation of fluid in the abdomen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth, sore mouth, bleeding in the mouth, inflammation in the gums</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow skin and eyes due to abnormally high levels of bilirubin in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating, night sweats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu‑like illness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Failure of multiple organs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal breakdown of red blood cells (hemolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in red blood cells count due to abnormal breakdown of red blood cells (hemolytic anaemia)</p><p>&nbsp;</p><p><strong>Uncommon: </strong><em>may affect up to 1 in 100&nbsp;people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness or paralysis of limbs or face, difficulty speaking (possible symptoms of stroke as a result of reduced blood supply)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warm or rapidly reddening skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough that produces phlegm or sometimes blood, fever, shortness of breath or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in controlling movement</p><p><strong>Rare</strong> (may affect up to 1 in 1 000 people)</p><p>A new type of cancer beginning in a type of white blood cells called T-cells (secondary malignancy of T-cell origin</p><p><strong>Not known: </strong><em>frequency cannot be estimated from the available data</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing or dizziness (possible symptoms of an allergic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness or numbness in the arms or legs, worsening of or loss of vision, having fixed and irrational thoughts that are not shared by others, headache, impaired memory or thinking, unusual behaviour</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The following information is intended for doctors only.</strong></p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the infusion bag label after EXP.</p><p>&nbsp;</p><p>Store and transport below ‑120&deg;C. Do not thaw the product until it is ready to be used.</p><p>&nbsp;</p><p>Do not use this medicine if the infusion bag is damaged or leaking.</p><p>&nbsp;</p><p>This medicine contains genetically‑modified blood cells. Local guidelines on handling of biological waste should be followed for unused medicine or waste material.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance of Kymriah is called tisagenlecleucel. Each infusion bag of Kmyriah contains tisagenlecleucel cell dispersion at a batch‑dependent concentration of autologous T cells genetically modified to express an anti‑CD19 chimeric antigen receptor (CAR‑positive viable T cells). 1 or more bags contain a total of 1.2&nbsp;x&nbsp;10<sup>6</sup>&nbsp;&ndash;&nbsp;6&nbsp;x&nbsp;10<sup>8 </sup>CAR+ viable T cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are glucose, sodium chloride, human albumin solution, dextran 40 for injection, dimethylsulfoxide, sodium gluconate, sodium acetate, potassium chloride, magnesium chloride, sodium‑N‑acetyltryptophanate, sodium caprylate, aluminium, and water for injections. See section&nbsp;2, &ldquo;Kymriah contains sodium, dimethylsulfoxide (DMSO) and dextran 40&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Kymriah is a cell dispersion for infusion. It is supplied as an infusion bag containing a cloudy to clear, colourless to slightly yellow dispersion of cells. Each bag contains 10 mL to 50 mL of dispersion.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novartis Europharm Limited</p><p>Vista Building</p><p>Elm Park, Merrion Road</p><p>Dublin 4</p><p>Ireland</p><p>www.Novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was approved by EMA in Aug-2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما دواء كيمرايا</strong></p><p dir="RTL">دواء كيمرايا، والمعروف أيضًا باسم تيساجنليسلوسيل، مصنوع من بعض خلايا الدم البيضاء الخاصة بك التي تُسمى الخلايا التائية. الخلايا التائية مهمة لجهاز المناعة (دفاعات الجسم) للعمل بشكل صحيح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل دواء كيمرايا؟</strong></p><p dir="RTL">يتم أخذ الخلايا التائية من دمك ثم يتم وضع جين جديد في الخلايا التائية بحيث يمكنها استهداف الخلايا السرطانية في جسمك. عندما يتم تسريب كيمرايا في دمك، ستعثر الخلايا التائية المعدلة على الخلايا السرطانية وتقتلها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استعمال كيمرايا</strong></p><p dir="RTL">يُستخدم كيمرايا لعلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان الدم الارومي الحاد ذي الخلايا البائية </strong><strong>(B‑cell ALL)</strong> - شكل من أشكال السرطان يصيب بعض الأنواع الأخرى من خلايا الدم البيضاء. يمكن استخدام الدواء لدى الأطفال والشباب حتى عمر 25 عامًا المصابين بهذا السرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان الغدد اللمفاوية المنتشر ذي الخلايا البائية الكبيرة (DLBCL)</strong> - شكل من أشكال السرطان يصيب بعض أنواع خلايا الدم البيضاء، معظمها في العقد الليمفاوية. يمكن استخدام الدواء للبالغين (18 عامًا أو أكثر) المصابين بهذا السرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان الغدد الليمفاوية الجريبي (FL)</strong> - شكل من أشكال السرطان يصيب بعض أنواع خلايا الدم البيضاء، معظمها في العقد الليمفاوية. يمكن استخدام الدواء للبالغين (18 عامًا أو أكثر) المصابين بهذا السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة حول كيفية عمل دواء كيمرايا أو سبب وصف هذا الدواء لك، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. موانع استعمال كيمرايا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه أي من مكونات هذا الدواء (المدرجة في القسم 6). إذا كنت تعتقد أنك تعاني من الحساسية، فاطلب الاستشارة من طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. الاحتياطات عند استعمال دواء كيمرايا</strong></p><p dir="RTL">كيمرايا مصنوع من خلايا الدم البيضاء الخاصة بك ويجب إعطاؤه لك فقط.</p><p dir="RTL">قد يصاب المرضى الذين عولجوا بدواء كيمرايا بأنواع جديدة من السرطان. وقد وردت تقارير عن إصابة مرضى بالسرطان، يبدأ في نوع من خلايا الدم البيضاء تسمى الخلايا التائية، بعد العلاج بدواء كيمرايا والأدوية المماثلة. تحدث إلى طبيبك إذا كنت تعاني من أي انتفاخ جديد في الغدد (العقد الليمفاوية) أو تغيرات في الجلد مثل الطفح الجلدي أو الكتل الجديدة.</p><p dir="RTL"><strong>قبل أن يتم إعطاؤك كيمرايا، يجب أن تُخبر طبيبك بما إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد خضعت لعملية زرع خلايا جذعية في آخر 4 أشهر. سيتحقق طبيبك مما إذا كانت لديك علامات أو أعراض لمرض الطعم ضد المضيف (GvHD). يحدث هذا عندما تهاجم الخلايا المزروعة جسمك، مما يُسبب أعراضًا مثل الطفح الجلدي، والغثيان، والتقيؤ، والإسهال، والبراز الدموي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من أي مشاكل في الرئة أو القلب أو ضغط الدم (انخفاض أو ارتفاع ضغط الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاحظت أن أعراض السرطان لديك تزداد سوءًا. إذا كنت تعاني من سرطان الدم، فقد يشمل ذلك الحمى، والشعور بالضعف، ونزف اللثة، و ظهور الكدمات. إذا كنت مصابًا باللمفومة، فقد يشمل ذلك الحمى غير المبررة، والشعور بالضعف، والتعرّق الليلي، وفقدان الوزن المفاجئ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بعدوى. ستتم معالجة العدوى قبل تسريب كيمرايا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من فيروس التهاب الكبد الوبائي &quot;ب&quot; أو التهاب الكبد الوبائي &quot;ج&quot; أو عدوى فيروس نقص المناعة البشرية (HIV).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملاً، أو تعتقدين أنكِ قد تكونين حاملاً، أو تخططين للحمل (انظري قسمي &quot;الحمل والرضاعة الطبيعية&quot; و&quot;منع الحمل للنساء والرجال&quot; أدناه).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد تلقيت لقاحًا في الأسابيع الستة الماضية أو تخطط للحصول على لقاح في الأشهر القليلة القادمة.</p><p dir="RTL">إذا انطبق عليك أي مما سبق (أو لم تكن متأكدًا)، فتحدث إلى طبيبك قبل إعطائك كيمرايا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاختبارات والفحوصات</strong></p><p dir="RTL"><strong>قبل أن يتم إعطاؤك كيمرايا</strong>، <strong>سيقوم طبيبك بما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص رئتيك، وقلبك، وضغط دمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البحث عن علامات العدوى؛ ستتم معالجة أي عدوى قبل إعطائك كيمرايا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التحقق مما إذا كانت اللمفومة أو سرطان الدم لديك يزداد سوءًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البحث عن علامات مرض الطعم ضد المضيف (GvHD) والذي يمكن أن يحدث بعد الزرع.</p><p dir="RTL"><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>فحص دمك بحثًا عن حمض اليوريك ولمعرفة عدد الخلايا السرطانية الموجودة في دمك. سيوضح هذا ما إذا كان من المحتمل أن تُصاب بحالة تُسمى متلازمة انحلال الورم. قد يتم إعطاؤك أدوية للمساعدة في الوقاية من هذه الحالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التحقق من عدم إصابتك بالتهاب الكبد الوبائي &quot;ب&quot; أو التهاب الكبد الوبائي&quot;ج&quot; أو عدوى فيروس نقص المناعة البشرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعد إعطائك كيمرايا</strong></p><p dir="RTL"><strong>أخبر طبيبك أو ممرضتك على الفور إذا كنت تعاني من أي مما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمّى، والتي قد تكون أحد أعراض عدوى. سيفحص طبيبك عدد خلايا الدم لديك بانتظام حيث قد ينخفض عدد خلايا الدم ومكونات الدم الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بقياس درجة حرارتك مرتين يوميًا لمدة 3-4 أسابيع بعد العلاج باستخدام كيمرايا. إذا كانت درجة حرارتك مرتفعة، فاستشر طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب الشديد والضعف وضيق التنفس، والتي قد تكون أعراضًا لنقص خلايا الدم الحمراء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف أو ظهورالكدمات بسهولة أكبر، واللذان قد يكونان عرضين لانخفاض مستويات الخلايا في الدم والمعروفة باسم الصفائح الدموية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون هناك تأثير على نتائج بعض أنواع اختبارات فيروس نقص المناعة البشرية - اسأل طبيبك عن ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيراقب طبيبك بانتظام عدد كريات دمك بعد تلقيك كيمرايا حيث قد تعاني من انخفاض في عدد خلايا الدم ومكونات الدم الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتبرع بالدم، أو الأعضاء، أو الأنسجة، أو الخلايا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يتم إجراء أي دراسات معتمدة على المرضى الأطفال دون 3 سنوات في حالة سرطان الدم الارومي الحاد ذي الخلايا البائية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام كيمرايا مع الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا لمعالجة سرطان الغدد اللمفاوية المنتشر ذي الخلايا البائية الكبيرة و سرطان الغدد الليمفاوية الجريبي وذلك لأن كيمرايا لم تتم دراسته في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج.</strong><strong> </strong><strong>التداخلات الدوائية من أخذ دواء كيمرايا مع أدوية أخرى أو أعشاب او مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيّة أدوية أخرى، بما في ذلك تلك التي يتم الحصول عليها من دون وصفة طبية. وذلك لأن الأدوية الأخرى يمكن أن تؤثر على طريقة عمل كيمرايا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، يجب ألا يتم إعطاؤك لقاحات معينة تُسمى اللقاحات الحية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الأسابيع 6 التي تسبق حصولك على الدورة القصيرة من العلاج الكيميائي (تُسمى العلاج الكيميائي المستنفد للخلايا اللمفاوية) لإعداد جسمك لخلايا كيمرايا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء العلاج بكيمرايا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد العلاج أثناء تعافي جهاز المناعة.</p><p dir="RTL">تحدث إلى طبيبك إذا كنت بحاجة إلى أخذ أي تطعيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل أن يتم إعطاؤك كيمرايا، أخبر طبيبك أو ممرضتك بما إذا كنت تتناول أي أدوية تضعف جهازك المناعي مثل الكورتيكوستيرويدات، لأن هذه الأدوية قد تؤثر على مفعول كيمرايا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د.</strong><strong> </strong><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للإنجاب، فاطلبي الاستشارة قبل تلقي هذا الدواء. وذلك لأن آثار كيمرايا على النساء الحوامل أو المرضعات غير معروفة، وقد يضر بجنينكِ أو طفلكِ حديث الولادة/الرضيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحتِ حاملاً أو كنتِ تعتقدين أنكِ قد تكونين حاملاً بعد تلقي العلاج بدواء كيمرايا، فتحدثي إلى طبيبكِ على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستخضعين لاختبار حمل قبل بدء العلاج. يجب إعطاؤكِ كيمرايا فقط إذا أظهرت النتيجة أنكِ لستِ حاملاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وسائل منع الحمل للنساء والرجال</strong></p><p dir="RTL">ناقشي إمكانية الحمل مع طبيبكِ المعالج إذا كنتِ قد تلقيتِ كيمرايا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقود السيارة، أو تستخدم الآلات، أو تشارك في الأنشطة التي تحتاج إلى الأنتباه. يمكن أن يُسبب دواء كيمرايا مشكلات مثل تغيرأو انخفاض الوعي، والارتباك، والنوبات في الأسابيع الثمانية التالية للتسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. معلومات مهمة حول بعض مكونات كيمرايا</strong></p><p dir="RTL"><strong>يحتوي كيمرايا على الصوديوم وثنائي ميثيل سلفوكسيد (DMSO) وديكستران 40.</strong></p><p dir="RTL">يحتوي هذا الدواء على 24.3 إلى 121.5 مجم من الصوديوم لكل جرعة. ويعادل ذلك من 1 إلى 6% من الحد الأقصى الموصى به للحصة الغذائية اليومية من الصوديوم المقدرة بـ 2 جم للبالغين. ويجب مراقبتك عن قرب خلال فترة التسريب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك كيمرايا دائمًا من قِبل طبيب في مركز علاج مؤهل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كيمرايا على خلايا دم بشرية. لذلك سيتخذ طبيبك الذي يتعامل مع كيمرايا الاحتياطات المناسبة (ارتداء القفازات والنظارات) لتفادي انتقال الأمراض المُعدية المحتملة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سحب دم لصنع كيمرايا</strong></p><p dir="RTL">يُصنع كيمرايا من خلايا الدم البيضاء الخاصة بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيأخذ طبيبك بعضًا من دمك باستخدام قسطرة توضع في وريدك (إجراء يُسمى فصادة الكريات البيضاء). يتم فصل بعض خلايا الدم البيضاء عن دمك وإعادة بقية دمك إلى وريدك. قد يستغرق ذلك الأمر من 3 إلى 6 ساعات وقد يلزم تكراره.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تجميد خلايا الدم البيضاء وإرسالها لصنع دواء كيمرايا. عادةً ما يستغرق صنع كيمرايا من 3 إلى 4 أسابيع ولكن قد يختلف الوقت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيمرايا هو علاج يتم تصنيعه خصيصًا لك. ثمة حالات لا يمكن فيها تصنيع كيمرايا بنجاح وإعطاؤه لك. في بعض الحالات، قد تتم محاولة تصنيع كيمرايا مرة أخرى.</p><p dir="RTL">قبل إعطاء كيمرايا، قد يعطيك طبيبك نوعًا من العلاج يُسمى العلاج الكيميائي المستنفد للخلايا اللمفاوية لبضعة أيام لتحضير جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج السرطان أثناء صنع كيمرايا</strong></p><p dir="RTL">خلال الفترة التي يتم فيها إنتاج كيمرايا، قد تتفاقم اللمفومة أو سرطان الدم لديك وقد يقرر طبيبك استخدام علاج إضافي (يُعرف باسم &quot;العلاج الإنتقالي&quot;) للحفاظ على استقرار السرطان لديك عن طريق منع نمو خلايا سرطانية جديدة. قد يؤدي هذا العلاج إلى الإصابة بآثار جانبية قد تكون شديدة أو مُهددة للحياة. سيخبرك طبيبك بالآثار الجانبية المحتملة لهذا العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية التي تُعطى مباشرةً قبل العلاج باستخدام كيمرايا</strong></p><p dir="RTL">خلال 30 إلى 60 دقيقة قبل أن يتم إعطاؤك كيمرايا، قد تتلقى أدوية أخرى. وذلك للمساعدة في منع &nbsp;تفاعلات التسريب والحمى. قد تشمل هذه الأدوية الأخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باراسيتامول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهيستامين مثل دايفنهيدرامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يتم إعطاؤك كيمرايا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتحقق طبيبك من أن المعلومات &nbsp;الفرديةالتعريفية للمريض الموضحة على كيس تسريب كيمرايا تتطابق .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيُعطيك طبيبك كيمرايا عن طريق التسريب، مما يعني أنه سيتم إعطاؤه في صورة تنقيط عبر أنبوب في وريدك. وعادةً ما يستغرق ذلك أقل من ساعة واحدة. سيتحقق طبيبك أثناء التسريب مما إذا كنت تعاني من صعوبة في التنفس أو دوخة (أعراض محتملة &nbsp;لتفاعلتحسسي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيمرايا هو علاج يؤخذ لمرة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعد إعطائك كيمرايا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يفضل الإقامة على بعد مسافة ساعتين من المستشفى الذي تُعالج فيه لمدة 4 أسابيع على الأقل بعد إعطائك كيمرايا. سيوصيك طبيبك بالعودة إلى المستشفى يوميًا لمدة 10 أيام على الأقل ينظر فيما إذا كنت بحاجة إلى البقاء في المستشفى كمريض منوم خلال أول 10 أيام بعد التسريب. وذلك حتى يتمكن طبيبك من التحقق إذا كان علاجك فعالاً ومساعدتك إذا كنت تعاني من أي آثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تغيبت عن موعد زيارة الطبيب، فاتصل بطبيبك أو المستشفى في أقرب وقت ممكن لتحديد موعد جديد للزيارة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور </strong>إذا تعرضت لأي من الآثار الجانبية التالية بعد تسريب كيمرايا. وعادةً ما تحدث في أول 8 أسابيع بعد التسريب، ولكنها قد تحدث أيضًا في وقت لاحق:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى شديدة وقشعريرة. قد يكون هذان عرضان يشيران إلى الإصابة بحالة خطيرة تُسمى متلازمة إفراز السيتوكين والتي قد تكون مُهددة للحياة أو مُميتة. الأعراض الأخرى لمتلازمة إطلاق السيتوكين هي صعوبة التنفس، والغثيان، والتقيؤ، والإسهال، وفقدان الشهية، والتعب، وألم العضلات، وألم المفاصل، والتورم، وانخفاض ضغط الدم، وسرعة ضربات القلب، والصداع، وقصور القلب والرئة والكلى، وإصابة الكبد. وتحدث هذه الأعراض دائمًا تقريبًا خلال أول 14 يومًا بعد التسريب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكلمن بينها تغيُّر التفكير أو انخفاض الوعي، وفقدان الاتصال بالواقع، والارتباك، والهياج، والنوبات، وصعوبة التحدث وفهم الكلام، وصعوبة المشي. قد تكون هذه أعراض حالة تُسمى متلازمة السُمية العصبية المرتبطة بالخلايا المناعية الفعالة (ICANS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون الشعور بالدفء، أو الحمى، أو القشعريرة، أو الارتجاف، أو التهاب الحلق، أو قرح الفم علامات على وجود عدوى. وقد تكون بعض حالات العدوى مُهددة للحياة أو مميتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحلل سريع لخلايا الورم مما يُسبب إفراز محتوياتها في مجرى الدم. يمكن أن يؤثر هذا على عمل أعضاء الجسم المختلفة، وخاصةً الكلى والقلب والجهاز العصبي (متلازمة انحلال الورم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة</strong></p><p dir="RTL">أدناه الآثار الجانبية الأخرى. إذا أصبحت هذه الآثار الجانبية شديدة أو خطيرة، فأخبر طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا:</strong> <em>قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شحوب الجلد، الضعف، ضيق التنفس بسبب انخفاض عدد خلايا الدم الحمراء أو انخفاض الهيموجلوبين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف مفرط أونزف يستمر لفترة طويلة أو كدمات بسبب انخفاض عدد الصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى مصحوبة بانخفاض خطير في عدد خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر الإصابة بعدوى بسبب انخفاض عدد خلايا الدم البيضاء بشكل غير طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى متكررة ومستمرة بسبب انخفاض الأجسام المضادة في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف، اضطراب نظم القلب، بسبب انخفاض مستوى أملاح الدم بشكل غير طبيعي بما في ذلك الفوسفور والبوتاسيوم والمغنيسيوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات إنزيمات الكبد أو الكرياتينين في الدم مما يُظهر أن كبدك أو كليتيك لا تعملان بشكل طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة أو غير منتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس، صعوبة في التنفس، سرعة في التنفس، سائل في الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن، إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العظام والظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الكاحلين والأطراف والوجه</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة:</strong> <em>(قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، توعك، تضخم الكبد، اصفرار الجلد والعينين، انخفاض عدد خلايا الدم بسبب التنشيط المناعي الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة أو إغماء، احمرار، طفح جلدي، حكة، حمى، ضيق في التنفس أو تقيؤ، ألم في البطن، إسهال بسبب &nbsp;تفاعل مرتبط&nbsp;بالتسريب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، غثيان، تقيؤ، إسهال بما في ذلك براز دموي (أعراض محتملة لمرض الطعم ضد المضيف (GvHD) وهو عندما تهاجم الخلايا المزروعة خلاياك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل بسبب ارتفاع مستوى حمض اليوريك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبار دم غير طبيعية (ارتفاع مستوى: الفوسفور، البوتاسيوم، الكالسيوم، المغنيسيوم والصوديوم، وهو إنزيم يُسمى الفوسفاتيز القلوي للمساعدة في اكتشاف أمراض الكبد، الفيبرين د-دايمر، مصل الفيريتين ؛ انخفاض مستوى: بروتين في الدم يُسمى &nbsp;الزلال (الألبومين)، الصوديوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج، نوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات/تقلصات عضلية بسبب انخفاض مستوى أملاح الدم بشكل غير طبيعي بما في ذلك الكالسيوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية أو لا يمكن السيطرة عليها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اهتزاز لاإرادي للجسم، صعوبة في الكتابة، صعوبة في التعبير عن الأفكار شفهيًا، ضعف الانتباه، النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل، صعوبة في الحركة بسبب تلف الأعصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العطش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الأعصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق والتهيج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة شديدة من الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر التنفس، صعوبة التنفس عند الاستلقاء، تورم القدمين أو الساقين (أعراض محتملة لفشل القلب)، توقف ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم وألم بسبب الجلطات الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم بسبب تسرب السوائل من الأوعية الدموية إلى الأنسجة المحيطة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاخ وعدم الراحة (انتفاخ البطن)، بسبب تراكم السوائل في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم، تقرح الفم، نزف في الفم، التهاب اللثة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين بسبب ارتفاع مستويات البيليروبين بشكل غير طبيعي في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق المفرط، التعرق الليلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض شبيه بالإنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل أعضاء متعددة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكسر غير طبيعي لخلايا الدم الحمراء (انحلال الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء بسبب تكسر غير طبيعي لخلايا الدم الحمراء (فقر الدم الانحلالي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: </strong><em>(قد تصيب ما يصل إلى شخص واحد من كل 100 أشخاص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو شلل في الأطراف أو الوجه، صعوبة في الكلام (أعراض محتملة للسكتة الدماغية نتيجة لانخفاض إمداد الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرارة في الجلد أو احمراره سريعاً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مصحوب ببلغم أو دم أحيانًا ، أو الحمى، أو ضيق التنفس، أو صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التحكم في الحركة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادر </strong><em>(قد يصيب ما يصل إلى شخص واحد من كل 1000 شخص)</em></p><p dir="RTL">&bull; نوع جديد من السرطان يبدأ في نوع من خلايا الدم البيضاء تسمى الخلايا التائية (خباثة ثانوية من أصل الخلايا التائية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة: </strong><em>لا يمكن تقدير معدل التكرار من البيانات المتاحة</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أو دوار (أعراض محتملة لتفاعل تحسسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو تنميل في الذراعين أو الساقين، تفاقم الرؤية أو فقدانها، وجود أفكار ثابتة وغير منطقية لا يشاركها الآخرون، صداع، ضعف الذاكرة أو التفكير، سلوك غير معتاد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، فتحدث مع الطبيب المتابع لك. وهذا يشمل أيّة آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المعلومات التالية مخصصة للأطباء فقط.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوَّن على ملصق كيس التسريب بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ ويُنقل في درجة حرارة أقل من -120 درجة مئوية. لا تقم بإذابته حتى يصبح جاهزًا للاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا كان كيس التسريب تالفًا أو به تسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج على خلايا دموية مُعدَّلة وراثيًا. يجب اتباع المبادئ التوجيهية المحلية بشأن التعامل مع النفايات البيولوجية فيما يتعلق بالدواء غير المستخدم أو النفايات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات كيمرايا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة الموجودة في كيمرايا تُسمى تيساجنليسلوسيل يحتوي كل كيس تسريب من كيمرايا على محلول خلايا تيساجنليسلوسيل بتركيز يعتمد على دفعة التصنيع من الخلايا التائية ذاتية المنشأ المعدلة وراثيًا للتعبير عن مستقبلات المستضدات الخيمرية المضادة لـ CD19 (خلايا تائية حية إيجابية لمستقبلات المستضدات الكيمرية). يحتوي كيس واحد أو أكثر على ما مجموعه 1.2 x 10<sup>6</sup>-6x10<sup>8 </sup>من خلايا تائية حية التي أضيفت لها مستقبلات المستضد الكيمري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي الجلوكوز، كلوريد الصوديوم، محلول الألبومين البشري، ديكستران 40 للحقن، ثنائي ميثيل سلفوكسيد، غلوكونات الصوديوم، أسيتات الصوديوم، كلوريد البوتاسيوم، كلوريد المغنيسيوم، صوديوم-إن-أسيتيل تريبتوفانات، كابريلات الصوديوم، الألومنيوم، وماء للحقن. انظر القسم 2، &quot;يحتوي كيمرايا على الصوديوم وثنائي ميثيل سلفوكسيد (DMSO) ودكستران 40&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ب. ماهو الشكل الصيدلاني لدواء كيمرايا ووصفه وحجم عبوته</strong></p><p dir="RTL">كيمرايا هو معلق خلايا مُعد للتسريب. يتم توفيره في كيس تسريب يحتوي على معلق من الخلايا غائم إلى الشفاف، عديم اللون مائل الى الإصفرار قليلاً. يحتوي كل كيس من 10 إلى 50 مل من المعلق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس يوروفارم المحدودة، أيرلندا.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر إعتماد لهذه النشرة من قِبل منظمة الأدوية الأوروبية في تاريخ 08/2024
	
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kymriah 1.2 x 106 – 6 x 108 cells dispersion for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kymriah is an immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti CD19 chimeric antigen receptor (CAR).
Qualitative and quantitative composition

Each ethylene vinyl acetate (EVA) infusion bag of Kymriah contains tisagenlecleucel cell dispersion at a batch dependent concentration of autologous T cells genetically modified to express an anti CD19 chimeric antigen receptor (CAR positive viable T cells) (see section 4.2).

The concentration of CAR positive viable T cells is dependent on indication and patient body weight (for B cell acute lymphoblastic leukaemia [ALL]). The cellular composition and the final cell number varies between individual patient batches. In addition to T cells, NK cells may be present. The quantitative information regarding CAR positive viable T cells/mL and total cells in the product is presented in the batch specific documentation accompanying Kymriah.

1 or more infusion bags containing a total of 1.2 x 106 to 6 x 108 CAR positive viable T cells.

Excipient with known effect

This medicinal product contains 2.43 mg sodium per mL and 24.3 to 121.5 mg sodium per dose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dispersion for infusion.

A colourless to slightly yellow dispersion.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Kymriah is indicated for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paediatric and young adult patients up to and including 25&nbsp;years of age with B‑cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post‑transplant or in second or later relapse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kymriah must be administered in a qualified treatment centre. Therapy should be initiated under the direction of and supervised by a healthcare professional experienced in the treatment of haematological malignancies and trained for administration and management of patients treated with Kymriah. Tocilizumab for use in the event of cytokine release syndrome (CRS) and emergency equipment must be available per patient prior to infusion. The treatment centre must have access to additional doses of tocilizumab within 8&nbsp;hours. In the exceptional case where tocilizumab is not available due to a shortage that is listed in the European Medicines Agency shortage catalogue, suitable alternative measures to treat CRS instead of tocilizumab must be available prior to infusion.</p><p>&nbsp;</p><p>Kymriah is intended for autologous use only (see section&nbsp;4.4). Manufacture and release of Kymriah usually takes about 3‑4&nbsp;weeks.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Dosage in paediatric and young adult B‑cell ALL patients</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients 50&nbsp;kg and below: 0.2 to 5&nbsp;x&nbsp;10<sup>6</sup> CAR‑positive viable T cells/kg body weight.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients above 50&nbsp;kg: 0.1 to 2.5&nbsp;x&nbsp;10<sup>8</sup> CAR‑positive viable T cells (non‑weight based).</p><p>&nbsp;</p><p><em><u>Dosage in adult DLBCL and FL patients</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.6 to 6&nbsp;x&nbsp;10<sup>8</sup> CAR‑positive viable T cells (non‑weight based).</p><p>&nbsp;</p><p><u>Pre‑treatment conditioning (lymphodepleting chemotherapy)</u></p><p>&nbsp;</p><p>The availability of Kymriah must be confirmed prior to starting the lymphodepleting regimen. For B‑cell ALL and DLBCL indications.</p><p>&nbsp;</p><p>Kymriah is recommended to be infused 2 to 14&nbsp;days after completion of the lymphodepleting chemotherapy. For FL, Kymriah is recommended to be infused 2 to 6&nbsp;days after completion of the lymphodepleting chemotherapy.</p><p>&nbsp;</p><p>Lymphodepleting chemotherapy may be omitted if a patient is experiencing significant cytopenia, e.g., white blood cell (WBC) count &le;1,000&nbsp;cells/&micro;L within one week prior to infusion.</p><p>&nbsp;</p><p>If there is a delay of more than 4&nbsp;weeks between completing lymphodepleting chemotherapy and the infusion and the WBC count is &gt;1,000&nbsp;cells/&mu;L, then the patient should be re‑treated with lymphodepleting chemotherapy prior to receiving Kymriah.</p><p>&nbsp;</p><p><em><u>B‑cell ALL</u></em></p><p>The recommended lymphodepleting chemotherapy regimen is:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fludarabine (30&nbsp;mg/m<sup>2</sup> intravenous daily for 4&nbsp;days) and cyclophosphamide (500&nbsp;mg/m<sup>2</sup> intravenous daily for 2&nbsp;days starting with the first dose of fludarabine).</p><p>&nbsp;</p><p>If the patient experienced a previous Grade&nbsp;4 haemorrhagic cystitis with cyclophosphamide, or demonstrated a chemorefractory state to a cyclophosphamide‑containing regimen administered shortly before lymphodepleting chemotherapy, then the following should be used:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytarabine (500&nbsp;mg/m<sup>2</sup> intravenous daily for 2&nbsp;days) and etoposide (150&nbsp;mg/m<sup>2</sup> intravenous daily for 3&nbsp;days starting with the first dose of cytarabine).</p><p>&nbsp;</p><p><em><u>DLBCL and FL</u></em></p><p>The recommended lymphodepleting chemotherapy regimen is:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fludarabine (25&nbsp;mg/m<sup>2</sup> intravenous daily for 3&nbsp;days) and cyclophosphamide (250&nbsp;mg/m<sup>2</sup> intravenous daily for 3&nbsp;days starting with the first dose of fludarabine).</p><p>&nbsp;</p><p>If the patient experienced a previous Grade&nbsp;4 haemorrhagic cystitis with cyclophosphamide, or demonstrated a chemorefractory state to a cyclophosphamide‑containing regimen administered shortly before lymphodepleting chemotherapy, then the following should be used:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bendamustine (90&nbsp;mg/m<sup>2</sup> intravenous daily for 2&nbsp;days).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pre‑medication</u></em></p><p>To minimise potential acute infusion reactions, it is recommended that patients be pre‑medicated with paracetamol and diphenhydramine or another H1 antihistamine within approximately 30 to 60&nbsp;minutes prior to Kymriah infusion. Corticosteroids should not be used at any time except in the case of a life‑threatening emergency (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Clinical assessment prior to infusion</u></p><p>&nbsp;</p><p>Kymriah treatment should be delayed in some patient groups at risk (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Monitoring after infusion</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients should be monitored daily for the first 10&nbsp;days following infusion for signs and symptoms of potential cytokine release syndrome, neurological events and other toxicities. Physicians should consider hospitalisation for the first 10&nbsp;days post infusion or at the first signs/symptoms of cytokine release syndrome and/or neurological events.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the first 10&nbsp;days following the infusion, the patient should be monitored at the physician&rsquo;s discretion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients should be instructed to remain within proximity (within 2&nbsp;hours of travel) of a qualified clinical facility for at least 4&nbsp;weeks following infusion.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><em>B-cell ALL</em>: No formal studies have been performed in paediatric patients below 3&nbsp;years of age.</p><p><em>DLBCL and FL</em>: The safety and efficacy of Kymriah in children and adolescents below 18&nbsp;years of age have not yet been established. No data are available.</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p><em>B‑cell ALL</em>: The safety and efficacy of Kymriah in this population have not been established.</p><p><em>DLBCL and FL</em>: No dose adjustment is required in patients over 65&nbsp;years of age.</p><p>&nbsp;</p><p><em><u>Patients seropositive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)</u></em></p><p>There is no experience with manufacturing Kymriah for patients with a positive test for HIV, active HBV, or active HCV infection. Leukapheresis material from these patients will not be accepted for Kymriah manufacturing. Screening for HBV, HCV, and HIV must be performed in accordance with clinical guidelines before collection of cells for manufacturing.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Kymriah is for intravenous use only.</p><p>&nbsp;</p><p><em><u>Precautions to be taken before handling or administering the medicinal product</u></em></p><p>This medicinal product contains genetically modified human blood cells. Healthcare professionals handling Kymriah should take appropriate precautions (wearing gloves and glasses) to avoid potential transmission of infectious diseases as for any human-derived material.</p><p>&nbsp;</p><p><em><u>Preparation for infusion</u></em></p><p>Prior to Kymriah infusion, it must be confirmed that the patient&rsquo;s identity matches the essential unique patient information on the infusion bag(s).</p><p>&nbsp;</p><p>The timing of thaw of Kymriah and infusion should be coordinated. Please refer to section&nbsp;6.6 for details on inspection and thawing of the infusion bag. The infusion start time should be confirmed in advance and adjusted for thaw so that Kymriah is available for infusion when the recipient is ready. Once Kymriah has been thawed and is at room temperature (20&deg;C ‑25&deg;C), it should be infused within 30&nbsp;minutes to maintain maximum product viability, including any interruption during the infusion.</p><p>&nbsp;</p><p><em><u>Administration</u></em></p><p>Kymriah should be administered as an intravenous infusion through latex‑free intravenous tubing without a leukocyte depleting filter, at approximately 10 to 20&nbsp;mL per minute by gravity flow. All contents of the infusion bag(s) should be infused. Sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection should be used to prime the tubing prior to infusion and to rinse it after infusion. When the full volume of Kymriah has been infused, the infusion bag should be rinsed with 10 to 30&nbsp;mL sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection by back priming to ensure as many cells as possible are infused into the patient.</p><p>&nbsp;</p><p>If the volume of Kymriah to be administered is &le;20&nbsp;mL, intravenous push may be used as an alternative method of administration.</p><p>&nbsp;</p><p>For special precautions for disposal see section&nbsp;6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Contraindications of the lymphodepleting chemotherapy must be considered.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>To ensure traceability the name of the product, the batch number and the name of the treated patient should be kept for a period of 30&nbsp;years.</p><p><u>&nbsp;</u></p><p><u>Reasons to delay treatment</u></p><p>&nbsp;</p><p>Due to the risks associated with Kymriah treatment, infusion should be delayed if a patient has any of the following conditions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unresolved serious adverse reactions (especially pulmonary reactions, cardiac reactions or hypotension) from preceding chemotherapies.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active uncontrolled infection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active graft‑versus‑host disease (GVHD).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significant clinical worsening of leukaemia burden or rapid progression of lymphoma following lymphodepleting chemotherapy.</p><p>&nbsp;</p><p><u>Blood, organ, tissue and cell donation</u></p><p>&nbsp;</p><p>Patients treated with Kymriah should not donate blood, organs, tissues or cells.</p><p>&nbsp;</p><p><u>Active central nervous system (CNS) leukaemia or lymphoma</u></p><p>&nbsp;</p><p>There is limited experience of use of Kymriah in patients with active CNS leukaemia and active CNS lymphoma. Therefore, the risk/benefit of Kymriah has not been established in these populations.</p><p>&nbsp;</p><p><u>Cytokine release syndrome</u></p><p>&nbsp;</p><p>Cytokine release syndrome, including fatal or life‑threatening events, has been frequently observed after Kymriah infusion (see section&nbsp;4.8). In almost all cases, development of cytokine release syndrome occurred between 1 to 10&nbsp;days (median onset 3&nbsp;days) after Kymriah infusion in paediatric and young adult B-cell ALL patients, between 1 and 9&nbsp;days (median onset 3&nbsp;days) after Kymriah infusion in adult DLBCL patients and between 1 to 14&nbsp;days (median onset 4&nbsp;days) after Kymriah infusion in adult FL patients. &nbsp;The median time to resolution of cytokine release syndrome was 8&nbsp;days in B-cell ALL patients, 7&nbsp;days in DLBCL patients and 4&nbsp;days in FL patients.</p><p>&nbsp;</p><p>Symptoms of cytokine release syndrome may include high fever, rigors, myalgia, arthralgia, nausea, vomiting, diarrhoea, diaphoresis, rash, anorexia, fatigue, headache, hypotension, dyspnoea, tachypnoea, hypoxia and tachycardia. Organ dysfunction, including cardiac insufficiency, renal insufficiency and liver injury with accompanying elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT) or elevated total bilirubin may also be observed. In some cases, disseminated intravascular coagulation (DIC) with low fibrinogen levels, capillary leak syndrome (CLS), macrophage activation syndrome (MAS) and haemophagocytic lymphohistiocytosis(HLH) may occur in the setting of cytokine release syndrome. Patients should be closely monitored for signs or symptoms of these events, including fever.</p><p>&nbsp;</p><p>Risk factors for severe cytokine release syndrome in paediatric and young adult B‑cell ALL patients are: high pre‑infusion tumour burden, uncontrolled or accelerating tumour burden following lymphodepleting chemotherapy, active infection and early onset of fever or cytokine release syndrome following Kymriah infusion. High tumour burden prior to Kymriah infusion was identified as a risk factor for developing severe cytokine release syndrome in adult DLBCL patients.</p><p>&nbsp;</p><p>Prior to administration of Kymriah in paediatric and young adult B-cell ALL patients, efforts should be made to lower and control the patient&rsquo;s tumour burden.</p><p>&nbsp;</p><p>In all indications, appropriate prophylactic and therapeutic treatment for infections should be provided, and complete resolution of any existing infections should be ensured. Infections may also occur during cytokine release syndrome and may increase the risk of a fatal event.</p><p>&nbsp;</p><p><em><u>Management of cytokine release syndrome associated with Kymriah</u></em></p><p>Cytokine release syndrome should be managed solely based on the patient&rsquo;s clinical presentation and according to the cytokine release syndrome management algorithm provided in Table&nbsp;1. Anti‑IL‑6 based therapy such as tocilizumab has been administered for moderate or severe cytokine release syndrome associated with Kymriah. One dose of tocilizumab per patient must be on site and available for administration prior to Kymriah infusion. The treatment centre should have access to additional doses of tocilizumab within 8&nbsp;hours. In the exceptional case where tocilizumab is not available due to a shortage that is listed in the European Medicines Agency shortage catalogue, the treatment centre must have access to suitable alternative measures instead of tocilizumab to treat CRS.</p><p>&nbsp;</p><p>Corticosteroids may be administered in cases of life‑threatening emergencies. Tisagenlecleucel continues to expand and persist following administration of tocilizumab and corticosteroids. Patients with medically significant cardiac dysfunction should be managed by standards of critical care and measures such as echocardiography should be considered. Tumour necrosis factor (TNF) antagonists are not recommended for management of Kymriah‑associated cytokine release syndrome.</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytokine release syndrome management algorithm</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Cytokine release syndrome severity</strong></p></td><td style="vertical-align:top"><p><strong>Symptomatic treatment</strong></p></td><td style="vertical-align:top"><p><strong>Tocilizumab</strong></p></td><td style="vertical-align:top"><p><strong>Corticosteroids</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mild symptoms requiring symptomatic treatment only, e.g.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; low fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; anorexia</p></td><td style="vertical-align:top"><p>Exclude other causes (e.g. infection) and treat specific symptoms with, for example, antipyretics, anti-emetics, analgesics, etc.</p><p>If neutropenic, administer antibiotics per local guidelines</p></td><td style="vertical-align:top"><p>Not applicable</p></td><td style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td style="vertical-align:top"><p>Symptoms requiring moderate intervention:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; high fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; hypoxia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; mild hypotension</p></td><td style="vertical-align:top"><p>Antipyretics, oxygen, intravenous fluids and/or low‑dose vasopressors as needed</p><p>Treat other organ toxicities as per local guidance</p></td><td rowspan="3"><p>If no improvement after symptomatic treatment administer tocilizumab intravenously over 1&nbsp;hour:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8&nbsp;mg/kg (max. 800&nbsp;mg) if body weight &ge;30&nbsp;kg</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp;mg/kg if body weight &lt;30&nbsp;kg</p><p>If no improvement, repeat every 8&nbsp;hours (max total of 4&nbsp;doses)*</p></td><td rowspan="3"><p>If no improvement within 12-18&nbsp;hours of tocilizumab, administer a daily dose of 2&nbsp;mg/kg intravenously methylprednisolone (or equivalent) until vasopressor and oxygen no longer needed, then taper*</p></td></tr><tr><td style="vertical-align:top"><p>Symptom requiring aggressive intervention:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; hypoxia requiring high-flow oxygen supplementation or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; hypotension requiring high-dose or multiple vasopressors</p></td><td style="vertical-align:top"><p>High-flow oxygen</p><p>Intravenous fluids and high-dose vasopressor(s)</p><p>Treat other organ toxicities as per local guidelines</p></td></tr><tr><td style="vertical-align:top"><p>Life-threatening symptoms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; haemodynamic instability despite intravenous fluids and vasopressors</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; worsening respiratory distress</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; rapid clinical deterioration</p></td><td style="vertical-align:top"><p>Mechanical ventilation Intravenous fluids and high-dose vasopressor(s)</p><p>Treat other organ toxicities as per local guidelines</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* If no improvement after tocilizumab and steroids, consider other anti-cytokine and anti-T‑cell therapies following institutional policy and published guidelines.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Alternative cytokine release syndrome management strategies may be implemented based on appropriate institutional or academic guidelines.</p><p>&nbsp;</p><p><u>Neurological adverse reactions</u></p><p>&nbsp;</p><p>Neurological events, in particular encephalopathy, confusional state or delirium, occur frequently with Kymriah and can be severe or life‑threatening (see section&nbsp;4.8). Other manifestations included depressed level of consciousness, seizures, aphasia and speech disorder. The majority of neurological events occurred within 8&nbsp;weeks following Kymriah infusion and were transient. The median time to onset of the first neurological events occurring at any time following Kymriah infusion was 8&nbsp;days in B‑cell ALL, 6&nbsp;days in DLBCL, and 9&nbsp;days in FL. The median time to resolution was 7&nbsp;days for B‑cell ALL, 13&nbsp;days for DLBCL, and 2&nbsp;days for FL. Neurological events can be concurrent with cytokine release syndrome, following resolution of cytokine release syndrome or in the absence of cytokine release syndrome.</p><p>&nbsp;</p><p>Patients should be monitored for neurological events. In case of neurological events, patients should be diagnostically worked up and managed depending on the underlying pathophysiology and in accordance with local standard of care.</p><p>&nbsp;</p><p><u>Infections and febrile neutropenia</u></p><p>&nbsp;</p><p>Patients with active, uncontrolled infection should not start Kymriah treatment until the infection is resolved. Prior to Kymriah infusion, infection prophylaxis should follow standard guidelines based on the degree of preceding immunosuppression.</p><p>&nbsp;</p><p>Serious infections, including life‑threatening or fatal infections, in some cases with late onset, occurred frequently in patients after Kymriah infusion (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of infection and treated appropriately. As appropriate, prophylactic antibiotics should be administered and surveillance testing should be employed prior to and during treatment with Kymriah. Infections are known to complicate the course and management of concurrent cytokine release syndrome. The possibility of opportunistic infections of the central nervous system should be considered in patients with neurological adverse events and appropriate diagnostic evaluations should be performed.</p><p>&nbsp;</p><p>&nbsp;</p><p>Febrile neutropenia was frequently observed in patients after Kymriah infusion (see section&nbsp;4.8) and may be concurrent with cytokine release syndrome. In the event of febrile neutropenia, infection should be evaluated and managed appropriately with broad‑spectrum antibiotics, fluids and other supportive care, as medically indicated.</p><p>&nbsp;</p><p>In patients achieving complete remission following Kymriah, resulting low immunoglobulin levels can increase the risk for infections. Attention to signs and symptoms of infection should be implemented according to age and standard specific guidelines.</p><p>&nbsp;</p><p><u>Prolonged cytopenias</u></p><p>&nbsp;</p><p>Patients may continue to exhibit cytopenias for several weeks following lymphodepleting chemotherapy and Kymriah infusion and should be managed according to standard guidelines. The majority of patients who had cytopenias at day&nbsp;28 following Kymriah treatment resolved to Grade&nbsp;2 or below within three months after treatment for paediatric ALL and DLBCL patients, and within six months for FL patients. Prolonged neutropenia has been associated with increased risk of infection. Myeloid growth factors, particularly granulocyte macrophage‑colony stimulating factor (GM‑CSF), have the potential to worsen cytokine release syndrome symptoms and are not recommended during the first 3&nbsp;weeks after Kymriah infusion or until cytokine release syndrome has resolved.</p><p>&nbsp;</p><p><u>Secondary malignancies</u> including of T-cell origin</p><p>&nbsp;</p><p>Patients treated with Kymriah may develop secondary malignancies or recurrence of their cancer. T-cell malignancies have been reported following treatment of haematological malignancies with a BCMA- or CD19-directed CAR T-cell therapy, including Kymriah. T-cell malignancies, including CAR-positive malignancies, have been reported within weeks and up to several years following administration of a CD19- or BCMA-directed CAR T-cell therapy. There have been fatal outcomes.&nbsp; Patients should be monitored life‑long for secondary malignancies. In the event that a secondary malignancy occurs, the company should be contacted to obtain instructions on patient samples to collect for testing.</p><p>&nbsp;</p><p><u>Hypogammaglobulinaemia</u></p><p>&nbsp;</p><p>Hypogammaglobulinaemia and agammaglobulinaemia can occur in patients after Kymriah infusion. Immunoglobulin levels should be monitored after treatment with Kymriah. In patients with low immunoglobulin levels pre‑emptive measures such as infection precautions, antibiotic prophylaxis and immunoglobulin replacement should be taken according to age and standard guidelines.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome (TLS)</u></p><p>&nbsp;</p><p>TLS, which may be severe, has occasionally been observed. To minimise risk of TLS, patients with elevated uric acid or high tumour burden should receive allopurinol, or an alternative prophylaxis, prior to Kymriah infusion. Signs and symptoms of TLS should be monitored and events managed according to standard guidelines.</p><p>&nbsp;</p><p><u>Concomitant disease</u></p><p>&nbsp;</p><p>Patients with a history of active CNS disorder or inadequate renal, hepatic, pulmonary or cardiac function were excluded from the studies. These patient are likely to be more vulnerable to the consequences of the adverse reactions described below and require special attention.</p><p>&nbsp;</p><p><u>Prior stem cell transplantation</u></p><p>&nbsp;</p><p>It is not recommended that patients receive Kymriah within 4&nbsp;months of undergoing an allogeneic stem cell transplant (SCT) because of the potential risk of Kymriah worsening GVHD. Leukapheresis for Kymriah manufacturing should be performed at least 12&nbsp;weeks after allogeneic SCT.</p><p><u>&nbsp;</u></p><p><u>Serological testing</u></p><p>&nbsp;</p><p>There is currently no experience with manufacturing Kymriah for patients testing positive for HBV, HCV and HIV.</p><p>&nbsp;</p><p>Screening for HBV, HCV and HIV must be performed in accordance with clinical guidelines before collection of cells for manufacturing. Hepatitis B virus (HBV) reactivation, can occur in patients treated with medicinal products directed against B cells and could result in fulminant hepatitis, hepatic failure and death.</p><p>&nbsp;</p><p><u>Prior treatment with anti‑CD19 therapy</u></p><p>&nbsp;</p><p>There is limited experience with Kymriah in patients exposed to prior CD19‑directed therapy. Kymriah is not recommended if the patient has relapsed with CD19‑negative leukaemia after prior anti‑CD19 therapy.</p><p>&nbsp;</p><p><u>Interference with serological testing</u></p><p>&nbsp;</p><p>Due to limited and short spans of identical genetic information between the lentiviral vector used to create Kymriah and HIV, some commercial HIV nucleic acid tests (NAT) may give a false positive result.</p><p>&nbsp;</p><p><u>Sodium and potassium content</u></p><p>&nbsp;</p><p>This medicinal product contains 24.3 to 121.5&nbsp;mg sodium per dose, equivalent to 1 to 6% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p><p>&nbsp;</p><p>This medicinal product contains potassium, less than 1&nbsp;mmol (39&nbsp;mg) per dose, i.e. essentially &ldquo;potassium‑free&rdquo;.</p><p>&nbsp;</p><p><u>Content of dextran 40 and dimethyl sulfoxide (DMSO)</u></p><p>&nbsp;</p><p>This medicinal product contains 11&nbsp;mg dextran 40 and 82.5&nbsp;mg dimethyl sulfoxide (DMSO) per mL. Each of these excipients are known to possibly cause anaphylactic reaction following parenteral administration. All patients should be observed closely during the infusion period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No pharmacokinetic or pharmacodynamic drug interaction studies with tisagenlecleucel have been performed. The co‑administration of agents known to inhibit T‑cell function has not been formally studied. Administration of low‑dose steroids as per the cytokine release syndrome treatment algorithm does not impact the expansion and persistence of CAR‑T cells. The co‑administration of agents known to stimulate T‑cell function has not been investigated and the effects are unknown.</p><p>&nbsp;</p><p><u>Live vaccines</u></p><p>&nbsp;</p><p>The safety of immunisation with live vaccines during or following Kymriah treatment has not been studied. Vaccination with live vaccines is not recommended for at least 6&nbsp;weeks prior to the start of lymphodepleting chemotherapy, during Kymriah treatment, and until immune recovery following treatment with Kymriah.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>&nbsp;</p><p>Pregnancy status for females of child‑bearing age should be verified prior to starting treatment with Kymriah.</p><p>&nbsp;</p><p>See the prescribing information for lymphodepleting chemotherapy for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy.</p><p>&nbsp;</p><p>There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with Kymriah.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of Kymriah in pregnant women. No animal studies have been conducted with Kymriah to assess whether it can cause foetal harm when administered to a pregnant woman (see section&nbsp;5.3). It is not known whether Kymriah has the potential to be transferred to the foetus via the placenta and could cause foetal toxicity, including B‑cell lymphocytopenia. Kymriah is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p>Pregnant women should be advised on the potential risks to the foetus. Pregnancy after Kymriah therapy should be discussed with the treating physician. Pregnant women who have received Kymriah may have hypogammaglobulinaemia. Assessment of immunoglobulin levels is indicated in newborns of mothers treated with Kymriah.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether Kymriah cells are excreted in human milk. A risk to the breast‑fed infant cannot be excluded. Women who are breast‑feeding should be advised of the potential risk to the breast‑fed infant.</p><p>&nbsp;</p><p>Following administration of Kymriah, breast‑feeding should be discussed with the treating physician.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data on the effect of Kymriah on fertility. Effects of Kymriah on male and female fertility have not been evaluated in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kymriah has major influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Due to the potential for neurological events, including altered mental status or seizures, patients receiving Kymriah are at risk for altered or decreased consciousness or coordination in the 8&nbsp;weeks following infusion.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a.Summary of the safety profile</u></p><p>&nbsp;</p><p>Safety assessment was based on a total of 291&nbsp;patients (with paediatric and young adult B-cell ALL ,DLBCL and FL) who received Kymriah in three multi-centre pivotal clinical studies.</p><p><em><u>&nbsp;</u></em></p><p><em><u>B‑cell ALL</u></em></p><p>The adverse reactions described in this section were characterised in 79&nbsp;patients infused with Kymriah in the multi-centre, pivotal clinical study CCTL019B2202.</p><p>&nbsp;</p><p>The most common non‑haematological adverse reactions were cytokine release syndrome (77%), infections (72%), hypogammaglobulinaemia (53%), pyrexia (42%) and decreased appetite (38%).</p><p>&nbsp;</p><p>The most common haematological laboratory abnormalities were decreased white blood cells (100%), decreased haemoglobin (100%), decreased neutrophils (100%), decreased lymphocytes (100%) and decreased platelets (97%).</p><p>&nbsp;</p><p>Grade&nbsp;3 and 4 adverse reactions were reported in 89% of patients. The most common Grade&nbsp;3 and 4 non‑haematological adverse reaction was cytokine release syndrome (48%).</p><p>&nbsp;</p><p>The most common Grade&nbsp;3 and 4 haematological laboratory abnormalities were white blood cells decreased (97%), lymphocytes decreased (96%), neutrophils decreased (95%), platelets decreased (77%) and haemoglobin decreased (48%).</p><p>&nbsp;</p><p>Grade&nbsp;3 and 4 adverse reactions were more often observed within the initial 8&nbsp;weeks post‑infusion (82% of patients) compared to after 8&nbsp;weeks post‑infusion (51% of patients).</p><p><em><u>&nbsp;</u></em></p><p><em><u>DLBCL</u></em></p><p>The adverse reactions described in this section were characterised in 115&nbsp;patients infused with Kymriah in one global multicentre international study, i.e. the ongoing pivotal clinical study CCTL019C2201.</p><p>&nbsp;</p><p>The most common non‑haematological adverse reactions were cytokine release syndrome (57%), infections (58%), pyrexia (35%), diarrhoea (31%), nausea (29%), fatigue (27%) and hypotension (25%).</p><p>&nbsp;</p><p>The most common haematological laboratory abnormalities were decreased lymphocytes (100%), decreased white blood cells (99%), decreased haemoglobin (99%), decreased neutrophils (97%), and decreased platelets (95%).</p><p>&nbsp;</p><p>Grade&nbsp;3 and 4 adverse reactions were reported in 88% of patients. The most common Grade&nbsp;3 and 4 non‑haematological adverse reactions were infections (34%) and cytokine release syndrome (23%).</p><p>&nbsp;</p><p>The most common (&gt;25%) Grade&nbsp;3 and 4 haematological laboratory abnormalities were lymphocyte count decreased (95%), neutrophil count decreased (82%), white blood cell count decreased (78%), haemoglobin decreased (59%) and platelet count decreased (56%).</p><p>&nbsp;</p><p>Grade&nbsp;3 and 4 adverse reactions were more often observed within the initial 8&nbsp;weeks post‑infusion (82%) compared to after 8&nbsp;weeks post‑infusion (48%).</p><p>&nbsp;</p><p><em><u>FL</u></em></p><p>The adverse reactions described in this section were characterised in 97&nbsp;patients infused with Kymriah in one global multicentre international study, i.e. the ongoing pivotal clinical study CCTL019E2202.</p><p>&nbsp;</p><p>The most common non‑haematological adverse reactions (&gt;25%) were cytokine release syndrome (50%), infections (50%) and headache (26%).</p><p>&nbsp;</p><p>The most common haematological laboratory abnormalities were decreased haemoglobin (94%), decreased lymphocytes (92%), decreased white blood cells (91%), decreased neutrophils (89%) and decreased platelets (89%).</p><p>&nbsp;</p><p>Grade&nbsp;3 and 4 adverse reactions were reported in 75% of patients. The most common Grade&nbsp;3 and 4 non‑haematological adverse reactions were infections (16%).</p><p>&nbsp;</p><p>The most common (&gt;25%) Grade&nbsp;3 and 4 haematological laboratory abnormalities were lymphocyte count decreased (87%), white blood cell count decreased (74%), neutrophil count decreased (71%), platelet count decreased (26%) and haemoglobin decreased (25%).</p><p>&nbsp;</p><p>Grade&nbsp;3 and 4 adverse reactions were more often observed within the initial 8&nbsp;weeks post‑infusion (70%) compared to after 8&nbsp;weeks post‑infusion (40%).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>b.Tabulated list of adverse drug reactions</u></em></p><p>The adverse reactions described in this section were identified in 79, 115 and 97&nbsp;patients in the ongoing multicentre pivotal clinical studies (CCTL019B2202, CCTL019C2201 and CCTL019E2202). and from post-marketing reporting Adverse drug reactions (Table&nbsp;2) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first, using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations<sup>1)</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Infections ‑ pathogen unspecified, viral infections, bacterial infections</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Fungal infections</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Secondary malignancy of T-cell origin</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Anaemia, haemorrhage<sup>2)</sup>, febrile neutropenia, neutropenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Haemophagocytic lymphohistiocytosis, leukopenia, pancytopenia, coagulopathy, lymphopenia, haemolysis, haemolytic anemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>B-cell aplasia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Cytokine release syndrome, hypogammaglobulinaemia<sup>3)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Infusion-related reaction, graft‑versus‑host disease<sup>4)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Decreased appetite, hypokalaemia, hypophosphataemia, hypomagnesaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypoalbuminaemia<sup>5)</sup>, hyperglycaemia, hyponatraemia, hyperuricaemia, hypercalcaemia, tumour lysis syndrome, hyperkalaemia, hyperphosphataemia, hypernatraemia, hypermagnesaemia, hyperferritinaemia<sup>6)</sup>, hypocalcaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Anxiety, delirium<sup>7)</sup>, sleep disorder<sup>8)</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache<sup>9)</sup>, encephalopathy<sup>10)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness<sup>11)</sup>, peripheral neuropathy<sup>12)</sup>, tremor<sup>13)</sup>, motor dysfunction<sup>14)</sup>, seizure<sup>15)</sup>, speech disorders<sup>16)</sup>, neuralgia<sup>17)</sup>, immune effector cell-associated neurotoxicity syndrome**</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Ischaemic cerebral infarction, ataxia<sup>18)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Neurotoxicity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Visual impairment<sup>19)</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Tachycardia<sup>20)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Cardiac failure<sup>21)</sup>, cardiac arrest, atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Ventricular extrasystoles</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hypotension<sup>22)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Thrombosis<sup>23)</sup>, capillary leak syndrome, hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Cough<sup>24)</sup>, dyspnoea<sup>25)</sup>, hypoxia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Oropharyngeal pain<sup>26)</sup>, pulmonary oedema<sup>27)</sup>, nasal congestion, pleural effusion, tachypnoea, acute respiratory distress syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Lung infiltration</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea, vomiting, constipation, abdominal pain<sup>28)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Stomatitis, abdominal distension, dry mouth, ascites</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased<sup>29)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Rash<sup>30)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pruritus, erythema, hyperhidrosis, night sweats</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Arthralgia, musculoskeletal pain<sup>31)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Acute kidney injury<sup>32)</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Pyrexia, fatigue<sup>33)</sup>, oedema<sup>34)</sup>, pain<sup>35)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Influenza‑like illness, asthenia, multiple organ dysfunction syndrome, chills</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Lymphocyte count decreased*, white blood cell count decreased*, haemoglobin decreased*, neutrophil count decreased*, platelet count decreased*</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Blood bilirubin increased, weight decreased, blood fibrinogen decreased, international normalised ratio increased, fibrin D dimer increased, activated partial thromboplastin time prolonged, prothrombin time prolonged</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections and infestations presented reflect high-level group terms.</p><p><sup>2)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemorrhage includes anal haemorrhage, blood blister, blood urine present, catheter site haemorrhage, cerebral haemorrhage, conjunctival haemorrhage, contusion, cystitis haemorrhagic, duodenal ulcer haemorrhage, disseminated intravascular coagulation, epistaxis, eye contusion, gastrointestinal haemorrhage, gingival bleeding, haematochezia, haemarthrosis, haematemesis, haematoma, haematuria, haemoptysis, heavy menstrual bleeding, large intestinal haemorrhage, melaena, mouth haemorrhage, mucosal haemorrhage, oral blood blister, peritoneal haematoma, petechiae, pharyngeal haemorrhage, post‑procedural haemorrhage, pulmonary haemorrhage, purpura, retinal haemorrhage, subdural haematoma, traumatic haematoma, tumour haemorrhage, upper gastrointestinal haemorrhage and vaginal haemorrhage.</p><p><sup>3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Hypogammaglobulinaemia includes immunoglobulins decreased, blood immunoglobulin A decreased, blood immunoglobulin G decreased, blood immunoglobulin M decreased, immunodeficiency, immunodeficiency common variable and hypogammaglobulinaemia.</p><p><sup>4)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Graft-versus-host Disease (GvHD) includes GvHD, GvHD in gastrointestinal tract, GvHD in skin</p><p><sup>5)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypoalbuminaemia includes blood albumin decreased, hypoalbuminaemia</p><p><sup>6)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperferritinaemia includes hyperferritinaemia, serum ferritin increased</p><p><sup>7)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delirium includes agitation, delirium, hallucination, hallucination visual, irritability and restlessness.</p><p><sup>8)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep disorder includes sleep disorder, insomnia and nightmare.</p><p><sup>9)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache includes headache and migraine.</p><p><sup>10)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy includes depressed level of consciousness, mental status changes, automatism, cognitive disorder, confusional state, disturbance in attention, encephalopathy, somnolence, lethargy, memory impairment, metabolic encephalopathy and thinking abnormal.</p><p><sup>11)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness includes dizziness, presyncope and syncope.</p><p><sup>12)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral neuropathy includes dysaesthesia, paraesthesia, peripheral sensory neuropathy, neuropathy peripheral, hyperaesthesia and hypoaesthesia.</p><p><sup>13)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremor includes dyskinesia and tremor.</p><p><sup>14)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Motor dysfunction includes muscle spasms, muscle twitching, myoclonus and myopathy.</p><p><sup>15)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizure includes seizure, generalised tonic-clonic seizures and status epilepticus.</p><p><sup>16)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Speech disorders includes speech disorders, dysarthria and aphasia.</p><p><sup>17)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuralgia includes neuralgia and sciatica.</p><p><sup>18)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ataxia includes ataxia and dysmetria.</p><p><sup>19)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual impairment includes vision blurred and visual impairment.</p><p><sup>20)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Tachycardia includes sinus tachycardia, supraventricular tachycardia, tachycardia</p><p><sup>21)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac failure includes cardiac failure, left ventricular dysfunction, cardiac failure congestive and right ventricular dysfunction.</p><p><sup>22)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension includes hypotension and orthostatic hypotension.</p><p><sup>23)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombosis includes deep vein thrombosis, embolism, pulmonary embolism, thrombosis, vena cava thrombosis and venous thrombosis.</p><p><sup>24)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough includes cough, productive cough and upper-airway cough syndrome.</p><p><sup>25)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea includes acute respiratory failure, dyspnoea, dyspnoea exertional, respiratory distress and respiratory failure.</p><p><sup>26)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oropharyngeal pain includes oral pain and oropharyngeal pain.</p><p><sup>27)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary oedema includes acute pulmonary oedema and pulmonary oedema.</p><p><sup>28)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain includes abdominal pain, abdominal pain upper and abdominal discomfort.</p><p><sup>29)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic enzyme increased includes alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, hepatic enzyme increased, transaminases increased.</p><p><sup>30)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash includes dermatitis, dermatitis acneiform, dermatitis contact, rash, rash maculo‑papular, rash papular and rash pruritic.</p><p><sup>31)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal pain includes back pain, bone pain, flank pain, musculoskeletal chest pain, musculoskeletal pain, neck pain, non-cardiac chest pain.</p><p><sup>32)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute kidney injury includes acute kidney injury, anuria, azotaemia, blood creatinine abnormal, blood creatinine increased, renal failure, renal tubular dysfunction and renal tubular necrosis.</p><p><sup>33)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue includes fatigue and malaise.</p><p><sup>34)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema includes fluid retention, fluid overload, oedema peripheral, generalised oedema, localised oedema, face oedema and peripheral swelling.</p><p><sup>35)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain includes pain and pain in extremity.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency is based on laboratory values. Patients are counted only for the worst grade observed post baseline.</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abbreviated as ICANS. Symptoms or signs can be progressive and may include aphasia, altered level of consciousness, impairment of cognitive skills, motor weakness, seizures, and cerebral oedema.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><u>c.Description of selected adverse drug reactions</u></p><p>&nbsp;</p><p><em><u>Cytokine release syndrome</u></em></p><p>In the ongoing clinical study in paediatric and young adult B‑cell ALL (N=79), cytokine release syndrome was reported in 77% of patients (48% with Grade&nbsp;3 or 4). Two deaths occurred within 30&nbsp;days of tisagenlecleucel infusion, including one patient, who died from progressive leukaemia in the setting of possible cytokine release syndrome and one patient who experienced fatal intracranial haemorrhage that developed during the course of resolved cytokine release syndrome, abdominal compartment syndrome, coagulopathy and renal failure.</p><p>&nbsp;</p><p>In the ongoing clinical study in DLBCL (N=115), cytokine release syndrome was reported in 57% of patients (23% with Grade&nbsp;3 or 4).</p><p>&nbsp;</p><p>In the ongoing clinical study in FL (N=97), cytokine release syndrome was reported in 50% of patients. No Grade&nbsp;3 or 4 events were reported.</p><p>Cytokine release syndrome was graded Penn criteria in the paediatric and young adult B-cell ALL and DLBCL studies as follows: Grade&nbsp;1:&nbsp;mild reactions, reactions requiring supportive care; Grade&nbsp;2:&nbsp;moderate reactions, reactions requiring intravenous therapies; Grade&nbsp;3:&nbsp;severe reactions, reactions requiring low‑dose vasopressors or supplemental oxygen; Grade&nbsp;4:&nbsp;life‑threatening reactions, those requiring high‑dose vasopressors or intubation; Grade&nbsp;5:&nbsp;death.</p><p>&nbsp;</p><p>Cytokine release syndrome was graded per the Lee criteria in the FL study as follows: Grade&nbsp;1: mild general symptoms requiring symptomatic treatment; Grade&nbsp;2: symptoms requiring moderate intervention such as low-flow oxygen supplementation or low-dose vasopressor; Grade&nbsp;3: symptoms requiring aggressive intervention, such as high-flow oxygen supplementation and high-dose vasopressor; Grade&nbsp;4: life‑threatening symptoms requiring intubation; Grade&nbsp;5: death.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>For clinical management of cytokine release syndrome, see section&nbsp;4.4 and Table&nbsp;1.</p><p>&nbsp;</p><p><em><u>Infections and febrile neutropenia</u></em></p><p>In B‑cell ALL patients severe infections (Grade&nbsp;3 and higher), which can be life‑threatening or fatal, occurred in 48% of patients after Kymriah infusion. The overall incidence (all grades) was 73% (unspecified 57%, viral 38%, bacterial 27% and fungal 15%) (see section&nbsp;4.4). 43% of the patients experienced an infection of any type within 8&nbsp;weeks after Kymriah infusion.</p><p>&nbsp;</p><p>In DLBCL patients severe infections (Grade&nbsp;3 and higher), which can be life‑threatening or fatal, occurred in 34% of patients. The overall incidence (all grades) was 58% (unspecified 48%, bacterial 15%, fungal 11% and viral 11%) (see section&nbsp;4.4). 37% of the patients experienced an infection of any type within 8&nbsp;weeks.</p><p>In FL patients severe infections (Grade&nbsp;3 or 4), occurred in 16% of patients. The overall incidence (all grades) was 50% (unspecified 36%, viral 17%, bacterial 6%, and fungal 2%) (see section&nbsp;4.4). 19% of the patients experienced an infection of any type within 8&nbsp;weeks.</p><p>&nbsp;</p><p>Severe febrile neutropenia (Grade&nbsp;3 or 4) was observed in 34% of paediatric and young adult B‑cell ALL patients, 17% of DLBCL patients and 12% of FL patients. See section&nbsp;4.4 for the management of febrile neutropenia before and after Kymriah infusion.</p><p>&nbsp;</p><p><em><u>Prolonged cytopenias</u></em></p><p>Cytopenias are very common based on prior chemotherapies and Kymriah therapy.</p><p>&nbsp;</p><p>All paediatric and young adult B‑cell ALL patients had a Grade&nbsp;3 or 4 cytopenia at some time after Kymriah infusion. Grade&nbsp;3 and 4 cytopenias not resolved by day&nbsp;28 after Kymriah infusion based on laboratory findings included decreased count of white blood cells (57%), neutrophils (54%), lymphocytes (44%), and thrombocytes (42%) and decreased haemoglobin (13%).</p><p>&nbsp;</p><p>All adult DLBCL patients had Grade&nbsp;3 and 4 cytopenias at some time after Kymriah infusion. Grade&nbsp;3 and 4 cytopenias not resolved by day&nbsp;28 based on laboratory findings included decreased count of thrombocytes (39%), lymphocytes (29%), neutrophils (25%), and white blood cells (21%) and decreased haemoglobin (14%).</p><p>&nbsp;</p><p>In adult patients with FL, 99% had Grade&nbsp;3 and 4 cytopenias at any time post Kymriah infusion. Grade&nbsp;3 and 4 cytopenias not resolved by day&nbsp;28 after Kymriah infusion based on laboratory findings included a decreased count of lymphocytes (23%), thrombocytes (17%), neutrophils (16%), white blood cells (13%) and decreased haemoglobin (3%).</p><p>&nbsp;</p><p><em><u>Neurological adverse reactions</u></em></p><p>The majority of neurotoxic events occurred within 8&nbsp;weeks following infusion and were transient.</p><p>&nbsp;</p><p>In paediatric and young adult B‑cell ALL patients, manifestations of encephalopathy and/or delirium occurred in 39% of patients (13% were Grade&nbsp;3 or 4) within 8&nbsp;weeks after Kymriah infusion. In DLBCL patients, manifestations of encephalopathy and/or delirium occurred in 20% of patients (11% were Grade&nbsp;3 or 4) within 8&nbsp;weeks after Kymriah infusion. In FL patients, these occurred in 9% of patients (1% Grade&nbsp;3 or 4) within 8&nbsp;weeks after Kymriah infusion. Among the neurotoxic events in FL patients, immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 4% of patients (1% Grade 3 or 4), all within 8&nbsp;weeks of Kymriah infusion.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Hypogammaglobulinaemia</u></em></p><p>Hypogammaglobulinaemia was reported in 53% of patients treated with Kymriah for r/r ALL, 17% of patients with r/r DLBCLand 17% of patients with r/r FL.</p><p>&nbsp;</p><p>Pregnant women who have received Kymriah may have hypogammaglobulinaemia. Immunoglobulin levels should be assessed in newborns of mothers treated with Kymriah.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>&nbsp;</p><p>In clinical studies, humoral immunogenicity of tisagenlecleucel was measured by determination of anti‑murine CAR19 antibodies (anti‑mCAR19) in serum pre‑ and post‑administration. The majority of patients tested positive for pre‑dose anti‑mCAR19 antibodies in paediatric and young adult ALL (B2202, 91.1%), adult DLBCL (C2201, 93.9%) and adult FL (E2202, 66.0%) patients.</p><p>&nbsp;</p><p>Treatment‑induced anti‑mCAR19 antibodies were found in 40.5% of paediatric and young adult ALL, 8.7% of adult DLBCL and 28.7% of adult FL patients. Pre‑existing and treatment‑induced antibodies were not associated with an impact on clinical response nor did they have an impact on the expansion and persistence of tisagenlecleucel. There is no evidence that the presence of pre‑existing and treatment‑induced anti‑mCAR19 antibodies impacts the safety or effectiveness of Kymriah.</p><p>&nbsp;</p><p>T‑cell immunogenicity responses were not observed in paediatric and young adult B‑cell ALL, adult r/r DLBCL and adult FL patients.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any complaint(s): complaints.ksa@novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents, ATC code: L01XX71.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Tisagenlecleucel is an autologous, immunocellular cancer therapy which involves reprogramming a patient&rsquo;s own T cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19 expressing cells. The CAR is comprised of a murine single chain antibody fragment which recognises CD19 and is fused to intracellular signalling domains from 4‑1BB (CD137) and CD3 zeta. The CD3 zeta component is critical for initiating T‑cell activation and antitumour activity, while 4‑1BB enhances the expansion and persistence of tisagenlecleucel. Upon binding to CD19‑expressing cells, the CAR transmits a signal promoting T‑cell expansion and persistence of tisagenlecleucel.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Acute lymphoblastic leukaemia (ALL)</u></em></p><p>The safety and efficacy of Kymriah treatment in paediatric and young adult patients with relapsed or refractory (r/r) B‑cell ALL were evaluated in one pivotal (B2202, N=79) and two supportive (B2205J and B2101J) open‑label, single‑arm studies (160&nbsp;patients in total, up to 25&nbsp;years of age). All patients had leukapheresis products collected and cryopreserved prior to or during study entry.</p><p>&nbsp;</p><p>The pivotal study B2202 (ELIANA) is a multicentre, single‑arm phase II study in paediatric and young adult patients with r/r B‑cell ALL. Of 97&nbsp;patients enrolled, 79 received infusion with Kymriah; for 8&nbsp;patients (8%) Kymriah could not be manufactured; reasons for discontinuation prior to Kymriah infusion included death (n=7; 7%) or adverse events (n=3; 3%) while awaiting Kymriah manufacturing in the clinical study. The median duration of study follow-up defined as the time from Kymriah infusion to the date of completion or discontinuation from follow-up prior to the data cut-off date was 16.0&nbsp;months (range: 0.4-34.4). The median time from Kymriah infusion to the data cut-off date was 24.2&nbsp;months (range: 4.5-35.1). The study is still ongoing.</p><p>&nbsp;</p><p>&nbsp;</p><p>Key baseline information for enrolled and infused patients is presented in Table&nbsp;3. The majority of patients (69/79, 87%) received bridging therapy while waiting for Kymriah. A total of 76 out of 79&nbsp;patients who received Kymriah infusion also received lymphodepleting chemotherapy after enrolment and prior to infusion of a single dose of Kymriah (see section&nbsp;4.2 for condition of lymphodepleting chemotherapy).</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study B2202: Baseline information across the enrolled and the infused patient population</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Enrolled</strong></p><p><strong>N=97</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Infused</strong></p><p><strong>N=79</strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Age (years)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean (standard deviation)</p></td><td style="vertical-align:top"><p>12 (5.48)</p></td><td style="vertical-align:top"><p>12 (5.38)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median (minimum &ndash; maximum)</p></td><td style="vertical-align:top"><p>11 (3 &ndash; 27)</p></td><td style="vertical-align:top"><p>11 (3 &ndash; 24)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age category (years) - n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;10&nbsp;years</p></td><td style="vertical-align:top"><p>40 (41.2)</p></td><td style="vertical-align:top"><p>32 (40.5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;10&nbsp;years and &lt;18&nbsp;years</p></td><td style="vertical-align:top"><p>40 (41.2)</p></td><td style="vertical-align:top"><p>33 (41.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;18&nbsp;years</p></td><td style="vertical-align:top"><p>17 (17.5)</p></td><td style="vertical-align:top"><p>14 (17.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex - n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Male</p></td><td style="vertical-align:top"><p>54 (55.7)</p></td><td style="vertical-align:top"><p>45 (57.0)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Female</p></td><td style="vertical-align:top"><p>43 (44.3)</p></td><td style="vertical-align:top"><p>34 (43)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease status -n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary refractory<sup>1</sup></p></td><td style="vertical-align:top"><p>8 (8.2)</p></td><td style="vertical-align:top"><p>6 (7.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relapsed disease<sup>2</sup></p></td><td style="vertical-align:top"><p>89 (91.8)</p></td><td style="vertical-align:top"><p>73 (92.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prior stem-cell transplantation - n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>39 (40.2)</p></td><td style="vertical-align:top"><p>31 (39.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p></td><td style="vertical-align:top"><p>50 (51.5)</p></td><td style="vertical-align:top"><p>42 (53.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>8 (8.2)</p></td><td style="vertical-align:top"><p>6 (7.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>Primary refractory: Never had a morphologic complete remission (CR) prior to the study;</p><p><sup>2</sup>Relapsed disease: Had at least one relapse prior to the study</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy was established through the primary endpoint of overall remission rate (ORR), which includes best overall response as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) within 3&nbsp;months post infusion, as determined by Independent Review Committee (IRC) assessment, as well as secondary endpoints including duration of remission (DOR) and the proportion of patients who achieved CR or CRi with minimal residual disease (MRD) &lt;0.01% by flow cytometry (MRD‑negative). See Table&nbsp;4 for efficacy results from this study. ORR was consistent across all subgroups. Eight patients who achieved CR/CRi after Kymriah infusion went to transplant while in remission. Kymriah was administered in a qualified Kymriah treatment centre in an inpatient and outpatient setting.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study B2202: Efficacy results in paediatric and young adult patients with relapsed/refractory B‑cell acute lymphoblastic leukaemia (ALL)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Primary endpoint</strong></p></td><td><p><strong>Enrolled patients</strong></p><p><strong>N=97</strong></p></td><td style="vertical-align:top"><p><strong>Infused patients</strong></p><p><strong>N=79</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall remission rate (ORR)<sup>1,2</sup>, n (%)</strong></p><p>95% CI</p></td><td style="vertical-align:top"><p><strong>65 (67.0)</strong></p><p>(56.7, 76.2)</p><p>p&lt;0.0001</p></td><td style="vertical-align:top"><p><strong>65 (82.3)</strong></p><p>(72.1, 90.0)</p><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; CR<sup>3</sup>, n (%)</p></td><td style="vertical-align:top"><p>49 (50.5)</p></td><td style="vertical-align:top"><p>49 (62.0)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; CRi<sup>4</sup>, n (%)</p></td><td style="vertical-align:top"><p>16 (16.5)</p></td><td style="vertical-align:top"><p>16 (20.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Key secondary endpoint</strong></p></td><td style="vertical-align:top"><p><strong>N=97</strong></p></td><td style="vertical-align:top"><p><strong>N=79</strong></p></td></tr><tr><td style="vertical-align:top"><p>CR or CRi with MRD negative bone marrow<sup>5,6</sup>, n (%)</p><p>95% CI</p></td><td style="vertical-align:top"><p>64 (66.0)</p><p>(55.7, 75.3)</p><p>p&lt;0.0001</p></td><td style="vertical-align:top"><p>64 (81.0)</p><p>(70.6, 89.0)</p><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of remission (DOR)</strong><sup>7</sup></p></td><td style="vertical-align:top"><p><strong>N=65</strong></p></td><td style="vertical-align:top"><p><strong>N=65</strong></p></td></tr><tr><td style="vertical-align:top"><p>% event free probability at 12&nbsp;months</p></td><td style="vertical-align:top"><p>66.3</p></td><td style="vertical-align:top"><p>66.3</p></td></tr><tr><td style="vertical-align:top"><p>% event free probability at 18&nbsp;months</p></td><td style="vertical-align:top"><p>66.3</p></td><td style="vertical-align:top"><p>66.3</p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td style="vertical-align:top"><p>Not reached (20.0, NE<sup>9</sup>)</p></td><td style="vertical-align:top"><p>Not reached (20.0, NE)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Other secondary endpoint</strong></p></td><td style="vertical-align:top"><p><strong>N=97</strong></p></td><td style="vertical-align:top"><p><strong>N=79</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall survival (OS)<sup>8</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; % survival probability at 12&nbsp;months</p></td><td style="vertical-align:top"><p>69.8</p></td><td style="vertical-align:top"><p>76.4</p></td></tr><tr><td style="vertical-align:top"><p>% survival probability at 24&nbsp;months</p></td><td style="vertical-align:top"><p>56.9</p></td><td style="vertical-align:top"><p>66.3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Median (months) (95% CI)</p></td><td style="vertical-align:top"><p>Not reached (19.4, NE)</p></td><td style="vertical-align:top"><p>Not reached (28.2, NE)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Requires remission status to be maintained for at least 28&nbsp;days without clinical evidence of relapse.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nominal one‑sided exact p‑value based on H0: ORR &le;20% vs. Ha: ORR &gt;20%</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CR (complete remission) was defined as &lt;5% of blasts in the bone marrow, circulating blasts in blood should be &lt;1%, no evidence of extramedullary disease, and full recovery of peripheral blood counts (platelets &gt;100,000/&mu;L and absolute neutrophil counts [ANC] &gt;1,000/&mu;L) without blood transfusion.</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CRi (complete remission with incomplete blood count recovery) was defined as &lt;5% of blasts in the bone marrow, circulating blasts in blood should be &lt;1%, no evidence of extramedullary disease, and without full recovery of peripheral blood counts with or without blood transfusion.</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MRD (minimal residual disease) negative was defined as MRD by flow cytometry &lt;0.01%.</p><p><sup>6</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nominal one‑sided exact p‑value based on H0: Rate of MRD negative remission &le;15% vs. Ha:&nbsp;&gt;15%.</p><p><sup>7</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DOR was defined as time since onset of CR or CRi to relapse or death due to underlying indication, whichever is earlier (N=65).</p><p><sup>8</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS was defined as time from date of Kymriah infusion to the date of death due to any cause for infused patients and from time of date of enrolment to the date of death due to any cause for enrolled patients.</p><p><sup>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Not estimable</p></td></tr></tbody></table><p>&nbsp;</p><p>Health‑related quality of life (HRQoL) was evaluated by PedsQL&trade; and EQ‑5D questionnaires completed by patients aged 8&nbsp;years and above (n=61). Among patients responding (n=51), the mean<u> </u>(SD) change from baseline in the PedsQL total score was 13.1 (13.45) at month&nbsp;3, 15.4 (16.81) at month&nbsp;6 and 25.0 (19.09) at month&nbsp;12, and the mean (SD) change from baseline in the EQ‑5D VAS score was 16.0 (16.45) at month&nbsp;3, 15.3 (18.33) at month&nbsp;6 and 21.7 (17.14) at month&nbsp;12, indicating overall clinically meaningful improvement in HRQoL following Kymriah infusion.</p><p>&nbsp;</p><p>The supportive study B2205J (ENSIGN) was a multicentre single-arm phase&nbsp;II study in paediatric and young adult patients with r/r B‑cell ALL. The study had similar study design and enrolled comparable patient populations as the pivotal study B2202. The main difference between the two studies was the definition of the primary efficacy endpoint ORR, which was measured within 6&nbsp;months after Kymriah infusion in study B2205J compared to 3&nbsp;months in the pivotal study. Of 75&nbsp;patients enrolled, 64 received infusion of Kymriah; for 5&nbsp;patients (6.7%), Kymriah could not be manufactured and 6&nbsp;patients (8.0%) died while awaiting Kymriah manufacturing in the clinical study. The median duration of study follow-up defined as the time from Kymriah infusion to the date of completion or discontinuation from follow-up prior to the data cut-off date in the final analyses was 12.2&nbsp;months (range: 0.4-49.3). The median time from Kymriah infusion to the data cut-off date was 31.7&nbsp;months (range: 17.6-56.0).</p><p>&nbsp;</p><p>Among the patients infused, the median age was 12.5&nbsp;years (range: 3 to 25), 34 (53.1%) were female and 30 (46.9%) were male, 10.9% had primary refractory disease, 89.1% had relapsed disease, and 43.8% of patients had at least one prior haematopoietic stem cell transplant. Baseline disease characteristics were similar in the enrolled patients with regard to age (median age 13.0&nbsp;years, range: 3 to 25), gender (46.7% female and 53.3% male), primary refractoriness (10.7%), and prior transplant history (42.7%). The majority of infused patients (57/64, 89.1%) received bridging chemotherapy while waiting for Kymriah. A total of 60 out of 64&nbsp;patients (93.8%) who received Kymriah infusion also received lymphodepleting chemotherapy after enrolment and prior to infusion of a single dose of Kymriah.</p><p>&nbsp;</p><p>Efficacy was established through the primary endpoint of ORR, which included best overall response as CR or CRi that were maintained for at least 28&nbsp;days within 6&nbsp;months post‑infusion, as determined by IRC assessment, as well as secondary endpoints including DOR, proportion of patients who achieved CR or CRi with MRD‑negative disease status, and OS. Among the patients infused, ORR was demonstrated in 45&nbsp;patients (70.3%; 59.4% CR and 10.9% CRi). CR/CRi with MRD‑negative bone marrow was reported in 43&nbsp;patients (67.2%). The median DOR was not reached and the event‑free probability at 12&nbsp;months was 70.5%. The survival probability at 24&nbsp;months was 54.7%, and the median OS was estimated as 29.9&nbsp;months (95% CI: 15.1, 42.4). The OS results were confirmed in an updated OS analyses (i.e. median OS 29.9&nbsp;months [95% CI: 15.2, NE] with 57.6% survival probability at 24&nbsp;months; with a median follow‑up for OS of 25.9&nbsp;months), which included patients transitioned to a separate long‑term follow‑up study. Seven patients (10.9%) who achieved CR/CRi after Kymriah infusion proceeded to haematopoietic stem cell transplant while in remission during the study, of which 5 of the patients (7.8%) proceeded to transplant within the first 6&nbsp;months post‑infusion. Efficacy results reported for the enrolled patients (n=75) demonstrate an ORR of 60.0% (50.7% CR and 9.3% CRi; 57.3% with MRD‑negative bone marrow). The reported overall survival in the enrolled population is in accordance with the infused population.</p><p>&nbsp;</p><p><em>Special populations</em></p><p>No differences in efficacy or safety were observed between different age subgroups.</p><p>&nbsp;</p><p><em>Patients with active CNS leukaemia</em></p><p>Of four patients with active CNS leukaemia (i.e. CNS‑3) included in study B2101J, three experienced cytokine release syndrome (Grade&nbsp;2‑4) and transient neurological abnormalities (Grade&nbsp;1‑3) that resolved within 1‑3&nbsp;months of infusion. One patient died due to disease progression and the remaining three patients achieved a CR or CRi and remain alive 1.5‑2&nbsp;years after infusion.</p><p>&nbsp;</p><p><em><u>Diffuse large B‑cell lymphoma (DLBCL)</u></em></p><p>The safety and efficacy of Kymriah treatment in adult patients with relapsed or refractory (r/r) diffuse large B‑cell lymphoma (DLBCL) who received &ge;2&nbsp;lines of chemotherapy, including rituximab and anthracycline, or relapsed following autologous haematopoietic stem cell transplantation (HSCT), was evaluated in an open‑label, pivotal, single‑arm study. Patients with T‑cell rich/histiocyte‑rich large B‑cell lymphoma (THRBCL), primary cutaneous large B‑cell lymphoma, primary mediastinal B‑cell lymphoma (PMBCL), EBV‑positive DLBCL of the elderly, Richter&rsquo;s transformation, and Burkitt lymphoma were not enrolled in study C2201.</p><p>&nbsp;</p><p>The pivotal study (C2201) is a multicentre, single‑arm phase II study in adult patients with relapsed or refractory DLBCL. Of 167&nbsp;patients enrolled, 115&nbsp;patients received infusion with Kymriah. Approximately 31% of patients discontinued the study prior to Kymriah infusion. For 13&nbsp;patients (8%) Kymriah could not be manufactured. Other reasons for discontinuation prior to Kymriah infusion included death (n=16; 10%), physician decision/primary disease progression (n=16; 10%), patient decision (n=2; 1%), protocol deviation (n=1; 1%) or adverse events (n=4; 2%) while awaiting Kymriah manufacturing in the clinical study. The median duration of study follow-up defined as the time from Kymriah infusion to date of completion or discontinuation from follow-up prior to the data cut-off date was 7.7&nbsp;months (range: 0.4-50.0). The median time from Kymriah infusion to the data cut-off date was 40.3&nbsp;months (range: 24.0-52.6). The study is still ongoing.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>Key baseline information for enrolled and infused patients is presented in Table&nbsp;5. All patients had leukapheresis starting material collected and cryopreserved prior to or during study entry. The majority of patients (103/115, 90%) received bridging therapy for disease stabilisation. The type and duration of bridging therapy was left to the discretion of the physician. 107/115&nbsp;patients (93%) received lymphodepleting chemotherapy prior to Kymriah infusion. Kymriah was given as a single‑dose (0.6‑6.0&nbsp;x&nbsp;10<sup>8</sup> CAR‑positive viable T cells) intravenous infusion in a qualified Kymriah treatment centre in an inpatient and outpatient setting.</p><p>&nbsp;</p><p><strong>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study C2201: Baseline information across the enrolled and the infused patient populations</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Enrolled</strong></p><p><strong>N=167</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Infused</strong></p><p><strong>N=115</strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Age (years)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean (standard deviation)</p></td><td style="vertical-align:top"><p>56 (12.9)</p></td><td style="vertical-align:top"><p>54 (13.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median (minimum &ndash; maximum)</p></td><td style="vertical-align:top"><p>58 (22 - 76)</p></td><td style="vertical-align:top"><p>56 (22 - 76)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age category (years) - n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;65&nbsp;years</p></td><td style="vertical-align:top"><p>120 (71.9)</p></td><td style="vertical-align:top"><p>89 (77.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;65&nbsp;years</p></td><td style="vertical-align:top"><p>47 (28.1)</p></td><td style="vertical-align:top"><p>26 (22.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex - n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Male</p></td><td style="vertical-align:top"><p>105 (62.9)</p></td><td style="vertical-align:top"><p>71 (61.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Female</p></td><td style="vertical-align:top"><p>62 (37.1)</p></td><td style="vertical-align:top"><p>44 (38.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prior haematopoietic stem cell transplant (SCT) - n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No</p></td><td style="vertical-align:top"><p>93 (55.7)</p></td><td style="vertical-align:top"><p>59 (51.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yes</p></td><td style="vertical-align:top"><p>74 (44.3)</p></td><td style="vertical-align:top"><p>56 (48.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stage III/IV disease at study entry - n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No</p></td><td style="vertical-align:top"><p>36 (21.6)</p></td><td style="vertical-align:top"><p>27 (23.5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yes</p></td><td style="vertical-align:top"><p>131 (78.4)</p></td><td style="vertical-align:top"><p>88 (76.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of prior lines of antineoplastic therapy &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p></td><td style="vertical-align:top"><p>6 (3.6)</p></td><td style="vertical-align:top"><p>5 (4.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>73 (43.7)</p></td><td style="vertical-align:top"><p>51 (44.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3</p></td><td style="vertical-align:top"><p>52 (31.1)</p></td><td style="vertical-align:top"><p>36 (31.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;4</p></td><td style="vertical-align:top"><p>36 (21.6)</p></td><td style="vertical-align:top"><p>23 (20.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease status -n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refractory to last line of therapy</p></td><td style="vertical-align:top"><p>98 (58.7)</p></td><td style="vertical-align:top"><p>63 (54.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relapse to last line of therapy</p></td><td style="vertical-align:top"><p>69 (41.3)</p></td><td style="vertical-align:top"><p>52 (45.2)</p></td></tr></tbody></table><p>&nbsp;</p><p>The efficacy of Kymriah was evaluated through the primary endpoint of best overall response rate (ORR), which includes complete response (CR) and partial response (PR) as determined by Independent Review Committee (IRC) assessment as well as secondary endpoints including duration of response (Table&nbsp;6).</p><p>&nbsp;</p><p><strong>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Study C2201: Efficacy results in adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:650px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Enrolled patients</strong></p><p><strong>N=167</strong></p></td><td style="vertical-align:top"><p><strong>Infused patients</strong></p><p><strong>N=115</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary endpoint<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>N=147</strong></p></td><td style="vertical-align:top"><p><strong>N=99</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response rate</strong> <strong>(ORR)</strong> (CR+PR)<sup>2</sup>, n (%)</p><p>95% CI</p></td><td style="vertical-align:top"><p><strong>53 (36.7)</strong></p><p>(28.9, 45.1)</p></td><td style="vertical-align:top"><p><strong>54 (54.5)</strong></p><p>(44.2, 64.6)</p></td></tr><tr><td style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>41 (27.9)</p></td><td style="vertical-align:top"><p>41(41.4)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>13 (8.8)</p></td><td style="vertical-align:top"><p>13 (13.1)</p></td></tr><tr><td style="vertical-align:top"><p>Response at month&nbsp;3</p></td><td style="vertical-align:top"><p>N=147</p></td><td style="vertical-align:top"><p>N=99</p></td></tr><tr><td style="vertical-align:top"><p>ORR (%)</p></td><td style="vertical-align:top"><p>40 (27.2)</p></td><td style="vertical-align:top"><p>40 (40.4)</p></td></tr><tr><td style="vertical-align:top"><p>CR (%)</p></td><td style="vertical-align:top"><p>34 (23.1)</p></td><td style="vertical-align:top"><p>34 (34.3)</p></td></tr><tr><td style="vertical-align:top"><p>Response at month&nbsp;6</p></td><td style="vertical-align:top"><p>N=147</p></td><td style="vertical-align:top"><p>N=99</p></td></tr><tr><td style="vertical-align:top"><p>ORR (%)</p></td><td style="vertical-align:top"><p>34 (23.1)</p></td><td style="vertical-align:top"><p>34 (34.3)</p></td></tr><tr><td style="vertical-align:top"><p>CR (%)</p></td><td style="vertical-align:top"><p>31 (21.1)</p></td><td style="vertical-align:top"><p>31 (31.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response (DOR)<sup>3</sup></strong></p></td><td style="vertical-align:top"><p><strong>N=54</strong></p></td><td style="vertical-align:top"><p><strong>N=54</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td style="vertical-align:top"><p>Not reached (10.0, NE<sup>5</sup>)</p></td><td style="vertical-align:top"><p>Not reached (10.0, NE<sup>5</sup>)</p></td></tr><tr><td style="vertical-align:top"><p>% relapse free probability at 12&nbsp;months</p></td><td style="vertical-align:top"><p>63.4</p></td><td style="vertical-align:top"><p>63.4</p></td></tr><tr><td style="vertical-align:top"><p>% relapse free probability at 18&nbsp;months</p></td><td style="vertical-align:top"><p>63.4</p></td><td style="vertical-align:top"><p>63.4</p></td></tr><tr><td style="vertical-align:top"><p>% relapse free probability at 24&nbsp;months</p></td><td style="vertical-align:top"><p>60.8</p></td><td style="vertical-align:top"><p>60.8</p></td></tr><tr><td style="vertical-align:top"><p>% relapse free probability at 30&nbsp;months</p></td><td style="vertical-align:top"><p>60.8</p></td><td style="vertical-align:top"><p>60.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Other secondary endpoints</strong></p></td><td style="vertical-align:top"><p><strong>N=167</strong></p></td><td style="vertical-align:top"><p><strong>N=115</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall survival (OS)<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>% survival probability at 12&nbsp;months</p></td><td style="vertical-align:top"><p>41.0</p></td><td style="vertical-align:top"><p>48.2</p></td></tr><tr><td style="vertical-align:top"><p>% survival probability at 24&nbsp;months</p></td><td style="vertical-align:top"><p>33.3</p></td><td style="vertical-align:top"><p>40.4</p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td style="vertical-align:top"><p>8.2 (5.8, 11.7)</p></td><td style="vertical-align:top"><p>11.1 (6.6, 23.9)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>The primary endpoint was analysed on all patients whose Kymriah was manufactured at the Novartis US facility.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORR is the proportion of patients with best overall response (BOR) of CR or PR based on the Lugano response criteria (Cheson 2014); non‑infused patients were assigned BOR=Unknown (i.e. non‑responders).</p><p><sup>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>DOR was defined as time from achievement of CR or PR to relapse or death due to DLBCL, whichever occurs first.</p><p><sup>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>OS was defined as time from date of Kymriah infusion to the date of death due to any cause (N=115) and time from date of enrolment to the date of death due to any cause for enrolled patients (N=167).</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not estimable.</p></td></tr></tbody></table><p>&nbsp;</p><p>Among 41&nbsp;patients who achieved CR, 15&nbsp;patients initially had an overall disease response of PR which improved to CR over time; most patients (13/16) achieved PR to CR conversion within 6&nbsp;months post-tisagenlecleucel infusion. ORR was consistent across subgroups.</p><p>&nbsp;</p><p><em><u>Follicular lymphoma (FL)</u></em></p><p>The safety and efficacy of Kymriah treatment in adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) were evaluated in an open label, multicentre, single-arm, phase&nbsp;II study (E2202, N=97).</p><p>&nbsp;</p><p>The pivotal study E2202 (ELARA) included patients who were refractory to or relapsed within 6&nbsp;months after completion of a second or later line of systemic therapy (including an anti-CD20 antibody and an alkylating agent), relapsed during or within 6&nbsp;months after completion of anti-CD20 antibody maintenance therapy following at least two lines of therapy, or relapsed after autologous haematopoietic stem cell transplant (HSCT). The study excluded patients with active or serious infections, transformed lymphoma or other aggressive lymphomas, including patients with FL Grade&nbsp;3b, those who had received prior allogeneic HSCT, or who had disease with active CNS involvement.</p><p>&nbsp;</p><p>Of 98&nbsp;patients who were enrolled and underwent leukapheresis, 97&nbsp;patients received infusion with Kymriah. One patient achieved a complete response prior to infusion which was attributed to their prior last line of therapy and was subsequently discontinued from the study due to physician decision prior to infusion. All patients had leukapheresis products collected and cryopreserved prior to or during study entry. Kymriah was delivered for all enrolled patients. The median duration of study follow-up defined as the time from Kymriah infusion to date of completion or discontinuation from follow-up prior to the data cut-off date was 18.6&nbsp;months (range: 1.8-29.9). The median time from Kymriah infusion to the data cut-off date was 20.8&nbsp;months (range: 14.4-29.9). The study is still ongoing.</p><p>&nbsp;</p><p>Of the 97&nbsp;patients infused with Kymriah, 94&nbsp;patients had measurable disease at baseline per Independent Review Committee (IRC) and are included in the efficacy analysis set (EAS).</p><p>&nbsp;</p><p>Key baseline information for the enrolled set and EAS is presented in Table&nbsp;7. Approximately half of the patients (44/94; 47%) received bridging therapy for disease stabilisation between leukapheresis and administration of Kymriah and all patients received lymphodepleting chemotherapy. For all infused patients, Kymriah was administered as a single dose intravenous infusion in a qualified treatment centre in an inpatient or outpatient (18%) setting.</p><p>&nbsp;</p><p><strong>Table&nbsp;7</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Study E2202: Baseline information across the enrolled and the EAS patient populations</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Enrolled</strong></p><p><strong>N=98</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>EAS*</strong></p><p><strong>N=94</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age (years)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean (standard deviation)</p></td><td style="vertical-align:top"><p>56.5 (10.34)</p></td><td style="vertical-align:top"><p>56.4 (10.54)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median (minimum &ndash; maximum)</p></td><td style="vertical-align:top"><p>57.5 (29-73)</p></td><td style="vertical-align:top"><p>57.0 (29-73)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age category (years) &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;65&nbsp;years</p></td><td style="vertical-align:top"><p>74 (75.5)</p></td><td style="vertical-align:top"><p>70 (74.5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;65&nbsp;years</p></td><td style="vertical-align:top"><p>24 (24.5)</p></td><td style="vertical-align:top"><p>24 (25.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Male</p></td><td style="vertical-align:top"><p>65 (66.3)</p></td><td style="vertical-align:top"><p>64 (68.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Female</p></td><td style="vertical-align:top"><p>33 (33.7)</p></td><td style="vertical-align:top"><p>30 (31.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stage III/IV disease at study entry &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>84 (85.7)</p></td><td style="vertical-align:top"><p>81 (86.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>High FLIPI score</strong><sup>1 </sup><strong>&ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>59 (60.2)</p></td><td style="vertical-align:top"><p>57 (60.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Bulky disease at baseline<sup>2</sup> &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>62 (63.3)</p></td><td style="vertical-align:top"><p>61 (64.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of prior lines of antineoplastic therapy &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>24 (24.5)</p></td><td style="vertical-align:top"><p>24 (25.5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3</p></td><td style="vertical-align:top"><p>21 (21.4)</p></td><td style="vertical-align:top"><p>19 (20.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p></td><td style="vertical-align:top"><p>25 (25.5)</p></td><td style="vertical-align:top"><p>24 (25.5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;5</p></td><td style="vertical-align:top"><p>28 (28.6)</p></td><td style="vertical-align:top"><p>27 (28.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Median (minimum &ndash; maximum)</p></td><td style="vertical-align:top"><p>4.0 (2.0 -13.0)</p></td><td style="vertical-align:top"><p>4.0 (2.0 - 13.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease status </strong><strong>&ndash; n </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refractory to last line of therapy</p></td><td style="vertical-align:top"><p>76 (77.6)</p></td><td style="vertical-align:top"><p>74 (78.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relapse to last line of therapy</p></td><td style="vertical-align:top"><p>17 (17.3)</p></td><td style="vertical-align:top"><p>17 (18.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Double refractory<sup>3 </sup></strong><strong>&ndash; n </strong><strong>(</strong><strong>%)</strong></p></td><td style="vertical-align:top"><p>67 (68.4)</p></td><td style="vertical-align:top"><p>65 (69.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression of disease within 24 months (POD24)<sup>4</sup> &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>61 (62.2)</p></td><td style="vertical-align:top"><p>61 (64.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prior haematopoietic stem cell transplant (HSCT) &ndash; n (%) </strong></p></td><td style="vertical-align:bottom"><p>36 (36.7)</p></td><td style="vertical-align:bottom"><p>35 (37.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prior PI3K inhibitor &ndash; n (%)</strong></p></td><td style="vertical-align:top"><p>21 (21.4)</p></td><td style="vertical-align:top"><p>19 (20.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infused patients who had measurable disease at baseline per Independent Review Committee (IRC) and are included in the efficacy analysis set.</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FLIPI includes 5 labelled prognostic factors; FLIPI&nbsp;=&nbsp;sum (where prognostic factor&nbsp;=&nbsp;&lsquo;Yes&rsquo;); Low: 0-1 criteria met; intermediate: 2 criteria met; high: 3 or more met.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bulky disease defined per IRC as imaging showing any nodal or extra nodal tumour mass that is &gt;7&nbsp;cm in diameter or involvement of at least 3 nodal sites, each with a diameter &gt;3&nbsp;cm.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double refractory is defined as patients who failed to respond or relapsed within 6&nbsp;months following therapy with anti-CD20 and alkylating agents, any regimen</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; POD24: subjects with primary refractory or experiencing progression of disease within 24&nbsp;months from initiation of a first-line anti-CD20 mAb containing treatment.</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy was evaluated through the primary endpoint of complete response rate (CRR), recorded from infusion until progressive disease or start of new therapy. CRR was determined by IRC based on Lugano classification criteria (Cheson 2014). Secondary endpoints included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS). Median time from enrolment to infusion was 46&nbsp;days (range: 23 to 127). The first disease assessment was scheduled to be performed at month&nbsp;3 post-infusion.</p><p>&nbsp;</p><p><strong>Table&nbsp;8 </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Study E2202: Efficacy results in adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of therapy</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:650px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Enrolled patients</strong></p><p><strong>N=98</strong></p></td><td style="vertical-align:top"><p><strong>EAS patients*</strong></p><p><strong>N=94</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Complete response rate</strong> <strong>(CRR)<sup>1</sup>, per IRC</strong></p><p>n (%)&nbsp;</p><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>67 (68.4)</p><p>(58.9, 78.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>65 (69.1)</p><p>(58.8, 78.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response rate (ORR)</strong><strong><sup>2</sup></strong><strong>, per IRC</strong></p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>84 (85.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>81 (86.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response (DOR)<sup>3</sup>, per IRC</strong></p></td><td style="vertical-align:top"><p><strong>N=84</strong></p></td><td style="vertical-align:top"><p><strong>N=81</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td style="vertical-align:top"><p>NE (20.9, NE)</p></td><td style="vertical-align:top"><p>NE (15.6, NE)</p></td></tr><tr><td style="vertical-align:top"><p>% event‑free probability at 9&nbsp;months (95% CI)</p></td><td style="vertical-align:top"><p>75.9 (64.8, 83.9)</p></td><td style="vertical-align:top"><p>76.2 (64.9, 84.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI=Confidence interval, NE=Not estimable</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infused patients who had measurable disease at baseline per Independent Review Committee (IRC) and are included in the efficacy analysis set.</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The primary endpoint was CRR per IRC based on Lugano response criteria (Cheson 2014) and defined as the proportion of patients with a best overall response (BOR) of complete response (CR). The non-infused patient was treated as a non-responder.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORR was defined as the proportion of patients with a BOR of CR or partial response (PR). The non-infused patient was treated as a non-responder.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DOR was defined as time from achievement of CR or PR to relapse or death due to FL, whichever occurs first.</p></td></tr></tbody></table><p>&nbsp;</p><p>All responders achieved their first response (CR or PR) at the first disease assessment performed post-infusion, at 3&nbsp;months. Of the 65&nbsp;patients who eventually achieved a CR, 15&nbsp;patients (16%) initially had a PR. The majority of patients converted from PR to CR within 6&nbsp;months post-infusion. No patient who received Kymriah infusion went to transplant while in response (CR or PR).</p><p>&nbsp;</p><p>The probability for a patient to remain in response (DOR) &ge;9&nbsp;months was 76% (95% CI: 64.9, 84.3), while the probability for a patient who achieved a CR to remain in response &ge;9&nbsp;months was 87% (95% CI: 75.6, 93.3).</p><p>&nbsp;</p><p>Subgroup analyses demonstrated a generally consistent CRR across all subgroups, including the following high-risk prognostic subgroups: high FLIPI score (CRR of 63%), prior HSCT (CRR of 66%), POD24 (CRR of 59%), and double refractoriness (CRR of 66%).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>There are not enough data to determine whether there are any differences in efficacy or safety between different age subgroups, although the clinical benefit and safety experience in elderly patients with DLBCL and FL above the age of 65&nbsp;years (23% and 24.7% of the study population for DLBCL and FL, respectively) were comparable to the overall population.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Kymriah in one or more subsets of the paediatric population in the following conditions: a)&nbsp;treatment of B‑cell lymphoblastic lymphoma, and b)&nbsp;treatment of mature B‑cell neoplasms (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following infusion of Kymriah into paediatric and young adult r/r B‑cell ALL, r/r DLBCL and r/r FL patients, tisagenlecleucel typically exhibited an initial rapid expansion followed by a slower bi‑exponential decline. High inter-subject variability was associated with the <em>in vivo</em> exposure metrics (AUC<sub>0-28d</sub> and C<sub>max</sub>) across all indications.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Cellular kinetics in paediatric and young adult B‑cell ALL patients</u></p><p>&nbsp;</p><p>A summary of cellular kinetic parameters of tisagenlecleucel in paediatric and young adult B‑cell ALL patients is provided in Table&nbsp;7 below. The maximal expansion (C<sub>max</sub>) was approximately 1.6‑fold higher in CR/CRi patients (n=103) compared with non‑responding (NR) patients (n=10) as measured by qPCR. Delayed and lower expansion was observed in NR patients compared to CR/CRi patients.</p><p><u>&nbsp;</u></p><p>Table&nbsp;9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cellular kinetic parameters of tisagenlecleucel in paediatric and young adult r/r B‑cell ALL (Studies B2202 and B2205J)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>Summary statistics</p></td><td style="vertical-align:top"><p>Responding patients (CR/CRi)</p><p>N=105</p></td><td style="vertical-align:top"><p>Non‑responding patients (NR)</p><p>N=12</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (copies/&mu;g)</p></td><td style="vertical-align:top"><p>Geometric mean (CV%), n</p></td><td style="vertical-align:top"><p>35,300 (154.0), 103</p></td><td style="vertical-align:top"><p>21,900 (80.7), 10</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>max</sub><sup>&Dagger;</sup> (day)</p></td><td style="vertical-align:top"><p>Median [min;max], n</p></td><td style="vertical-align:top"><p>9.83 [5.70; 27.8], 103</p></td><td style="vertical-align:top"><p>20.1 [12.6; 62.7], 10</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0‑28d </sub>(copies/&mu;g*day)</p></td><td style="vertical-align:top"><p>Geometric mean (CV%), n</p></td><td style="vertical-align:top"><p>309,000 (178.1), 103</p></td><td style="vertical-align:top"><p>232,000 (104.5), 8</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>&frac12;</sub> (day)</p></td><td style="vertical-align:top"><p>Geometric mean (CV%), n</p></td><td style="vertical-align:top"><p>25.2 (307.8), 71</p></td><td style="vertical-align:top"><p>3.80 (182.4), 4</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>last</sub></p></td><td style="vertical-align:top"><p>Median [min;max], n</p></td><td style="vertical-align:top"><p>166 [20.9; 916], 103</p></td><td style="vertical-align:top"><p>28.8 [26.7; 742], 9</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Cellular kinetics in adult DLBCL patients</u></p><p>&nbsp;</p><p>A summary of cellular kinetic parameters of tisagenlecleucel in DLBCL patients is provided in Table&nbsp;10 below.</p><p>&nbsp;</p><p>Table&nbsp;10&nbsp;&nbsp;&nbsp;&nbsp; Cellular kinetic parameters of tisagenlecleucel in r/r DLBCL patients</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>Summary statistics</p></td><td style="vertical-align:top"><p>Responding patients</p><p>(CR and PR)</p><p>N=43</p></td><td style="vertical-align:top"><p>Non‑responding patients</p><p>(SD/PD/Unknown)</p><p>N=72</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (copies/&mu;g)</p></td><td style="vertical-align:top"><p>Geometric mean (CV%), n</p></td><td style="vertical-align:top"><p>5,840 (254.3), 43</p></td><td style="vertical-align:top"><p>5,460 (326.89), 65</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>max</sub> (day)</p></td><td style="vertical-align:top"><p>Median [min;max], n</p></td><td style="vertical-align:top"><p>9.00 [5.78; 19.8], 35</p></td><td style="vertical-align:top"><p>8.84 [3.04; 27.7], 65</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0‑28d </sub>(copies/&mu;g*day)</p></td><td style="vertical-align:top"><p>Geometric mean (CV%), n</p></td><td style="vertical-align:top"><p>61,200 (177.7), 40</p></td><td style="vertical-align:top"><p>67,000 (275.2), 56</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>&frac12;</sub> (day)</p></td><td style="vertical-align:top"><p>Geometric mean (CV%), n</p></td><td style="vertical-align:top"><p>129 (199.2), 33</p></td><td style="vertical-align:top"><p>14.7 (147.1), 44</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>last</sub></p></td><td style="vertical-align:top"><p>Median [min;max], n</p></td><td style="vertical-align:top"><p>551 [17.1; 1030], 43</p></td><td style="vertical-align:top"><p>61.4 [19.8; 685], 56</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Cellular kinetics in FL patients</u></p><p>&nbsp;</p><p>A summary of cellular kinetic parameters of tisagenlecleucel in FL patients by BOR is provided in Table&nbsp;11 below.</p><p>&nbsp;</p><p>The geometric mean AUC<sub>0-28d</sub> value of responders was 2.9&nbsp;fold higher compared to non-responders, while the geometric mean C<sub>max</sub> value was 2.1&nbsp;fold higher in responders compared to non-responders.</p><p>&nbsp;</p><p>Table&nbsp;11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cellular kinetic parameters of tisagenlecleucel in r/r FL patients</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>Summary statistics</p></td><td style="vertical-align:top"><p>Responding patients</p><p>(CR and PR)</p><p>N=81</p></td><td style="vertical-align:top"><p>Non-responding patients</p><p>(SD/PD)</p><p>N=12</p></td></tr><tr><td><p>C<sub>max</sub> (copies/micrograms)</p></td><td><p>Geometric mean (CV%), n</p></td><td><p>6280 (331), 67</p></td><td><p>3000 (1190), 8</p></td></tr><tr><td><p>T<sub>max</sub> (day)</p></td><td><p>Median [min;max], n</p></td><td><p>9.92 [2.62; 28.0], 67</p></td><td><p>13.0 [7.73; 16.0], 8</p></td></tr><tr><td><p>AUC<sub>0-28d </sub>(copies/micrograms*day)</p></td><td><p>Geometric mean (CV%), n</p></td><td><p>57500 (261), 66</p></td><td><p>20100 (18100), 7</p></td></tr><tr><td><p>T<sub>&frac12; </sub>(day)</p></td><td><p>Geometric mean (CV%), n</p></td><td><p>43.8 (287), 43</p></td><td><p>24.4 (180), 6</p></td></tr><tr><td><p>T<sub>last</sub> (day)</p></td><td><p>Median [min;max], n</p></td><td><p>191 [19.9; 558], 73</p></td><td><p>107 [18.7; 366], 10</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>In paediatric and young adult B‑cell ALL patients, tisagenlecleucel has been shown to be present in the blood and bone marrow beyond 2&nbsp;years. The blood to bone marrow partitioning of tisagenlecleucel in bone marrow was 47.2% of that present in blood at day&nbsp;28 while at months&nbsp;3 and 6 it distributes at 68.3% and 69%, respectively (Studies&nbsp;B2202 and B2205J). Tisagenlecleucel also traffics and persists in cerebrospinal fluid in paediatric and young adult B‑cell ALL patients (Study B2101J) for up to 1&nbsp;year.</p><p>&nbsp;</p><p>In adult DLBCL patients (Study C2201), tisagenlecleucel has been detected for up to 3&nbsp;years in peripheral blood and up to month&nbsp;9 in bone marrow for complete responder patients. The blood to bone marrow partitioning in bone marrow was nearly 70% of that present in blood at day&nbsp;28 and 50% at month&nbsp;3 in both responder and non‑responder patients.</p><p>&nbsp;</p><p>In adult FL patients (Study E2202), tisagenlecleucel has been detected for up to 18&nbsp;months in peripheral blood and up to month&nbsp;3 in bone marrow for complete responder patients. The blood to bone marrow partitioning in bone marrow was nearly 54% of that present in blood at month&nbsp;3 in both responder and non-responder patients.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The elimination profile of Kymriah includes a bi‑exponential decline in peripheral blood and bone marrow.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>&nbsp;</p><p>There is no apparent relationship between dose and AUC<sub>0‑28d</sub> or C<sub>max</sub>.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>The scatter plots of cellular kinetic parameters versus age (22 to76&nbsp;years in DLBCL patients and 29 to 73&nbsp;years in FL patients) revealed no relevant relationship between cellular kinetic parameters (AUC<sub>0‑28d</sub> and C<sub>max</sub>) with age.</p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>Gender has not been identified asa significant characteristic influencing tisagenlecleucel expansion in B‑cell ALL, DLBCL and FL patients. In Study B2202, there were 43% female and 57% male patients, in Study C2201 38% female and 62% male patients and in Study E2202 34% female and 66% male patients who received Kymriah. Further, in Study E2202, the geometric means of the exposure parameters (C<sub>max</sub> and AUC<sub>0-28d</sub>) were shown to be 111% and 106% higher, respectively, in female patients compared to male patients. Although the interpretation of expansion in relation to gender is difficult due to overlapping ranges and high inter‑subject variability.</p><p>&nbsp;</p><p><em><u>Race/ethnicity</u></em></p><p>There is limited evidence that race/ethnicity impact the expansion of Kymriah in paediatric and young adult ALL ,DLBCL and FL patients. In Studies B2202 there were 73.4% Caucasian, 12.7% Asian and 13.9% other ethnic patients. In Study C2201 there were 85% Caucasian, 9% Asian, 4% Black or African American patients, and 3&nbsp;patients (3%) of unknown race. In Study E2202, there were 75% Caucasian, 13% Asian, 1% Black or African American patients, and 10% of unknown race.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Body weight</u></em></p><p>In ALL, DLBCL and FL patients, across the weight ranges (ALL; 14.4 to 137&nbsp;kg; DLBCL: 38.4 to 186.7&nbsp;kg; FL: 44.3 to 127.7&nbsp;kg), the scatter plots of qPCR cellular kinetic parameters versus weight revealed no apparent relationship between cellular kinetic parameters with weight.</p><p>&nbsp;</p><p><em><u>Prior transplantation</u></em></p><p>Prior transplantation did not impact the expansion/persistence of Kymriah in paediatric and young adult B‑cell ALL patients, adult DLBCL or adult FL patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical safety assessment of Kymriah addressed the safety concerns of potential uncontrolled cell growth of transduced T cells <em>in vitro</em> and <em>in vivo</em> as well as dose‑related toxicity, biodistribution and persistence. No such risks were identified based on these studies.</p><p>&nbsp;</p><p><u>Carcinogenicity and mutagenicity</u></p><p>&nbsp;</p><p>Genotoxicity assays and carcinogenicity studies in rodents are not appropriate to assess the risk of insertional mutagenesis for genetically‑modified cell therapy products. No alternative adequate animal models are available.</p><p>&nbsp;</p><p><em>In vitro</em> expansion studies with CAR‑positive T cells (Kymriah) from healthy donors and patients showed no evidence for transformation and/or immortalisation of T cells. <em>In vivo</em> studies in immunocompromised mice did not show signs of abnormal cell growth or signs of clonal cell expansion for up to 7&nbsp;months, which represents the longest meaningful observation period for immunocompromised mouse models. A genomic insertion site analysis of the lentiviral vector was performed on Kymriah products from 14&nbsp;individual donors (12&nbsp;patients and 2&nbsp;healthy volunteers). There was no evidence for preferential integration near genes of concern or preferential outgrowth of cells harbouring integration sites of concern.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p>&nbsp;</p><p>No non‑clinical reproductive safety studies were conducted as no adequate animal model is available.</p><p>&nbsp;</p><p><u>Juvenile animal studies</u></p><p>&nbsp;</p><p>Juvenile toxicity studies were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glucose</p><p>Sodium chloride</p><p>Human albumin solution</p><p>Dextran 40 for injection</p><p>Dimethylsulfoxide</p><p>Sodium gluconate</p><p>Sodium acetate</p><p>Potassium chloride</p><p>Magnesium chloride</p><p>Sodium‑N‑acetyltryptophanate</p><p>Sodium caprylate</p><p>Aluminium</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                9 months.

The product should be administered immediately after thawing. After thawing, the product should be kept at room temperature (20°C 25°C) and infused within 30 minutes to maintain maximum product viability, including any interruption during the infusion.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport below ‑120&deg;C, e.g. in a container for cryogenic storage (Dewar) in the vapour phase of liquid nitrogen.</p><p>&nbsp;</p><p>Store in the original protective envelope (Tyvek) containing the cassette protecting the infusion bag.</p><p>&nbsp;</p><p>For storage conditions after thawing of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethylene vinyl acetate (EVA) infusion bag with polyvinyl chloride (PVC) tubing and a luer spike interconnector closed by a luer‑lock cap containing either 10&ndash;30&nbsp;mL (50&nbsp;mL bags) or 30&ndash;50&nbsp;mL (250&nbsp;mL bags) cell dispersion.</p><p>&nbsp;</p><p>Each infusion bag is placed into an aluminum cassette, then put in a plastic overwrap bag with absorbent sheets and sealed in a protective envelope (Tyvek).</p><p>&nbsp;</p><p>One individual treatment dose comprises 1 or more infusion bags.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Inspection and thawing of the infusion bag(s)</u></p><p>&nbsp;</p><p>Do not thaw the product until it is ready to be used.</p><p>&nbsp;</p><p>The infusion bag should be placed inside a second sterile bag during thawing to protect ports from contamination and avoid spills in the unlikely event of the bag leaking. Kymriah should be thawed at 37&deg;C using either a water bath or dry thaw method until there is no visible ice in the infusion bag. The bag should be removed immediately from the thawing device and kept at room temperature (20&deg;C‑25&deg;C) until infusion. If more than one infusion bag has been received for the treatment dose, the next bag should only be thawed after the contents of the preceding bag have been infused.</p><p>&nbsp;</p><p>Kymriah should <u>not</u> be manipulated. For example, Kymriah should not be washed (spun down and resuspended in new media) prior to infusion.</p><p>&nbsp;</p><p>The infusion bag(s) should be examined for any breaks or cracks prior to thawing. If the infusion bag appears to have been damaged or to be leaking, it should not be infused and should be disposed of according to local procedures on handling of biological waste (see section&nbsp;4.2.).</p><p>&nbsp;</p><p><u>Precautions to be taken for transport and disposal of the medicinal product</u></p><p>&nbsp;</p><p>Kymriah should be transported within the facility in closed, break‑proof, leak‑proof containers.</p><p>&nbsp;</p><p>Kymriah contains genetically‑modified human blood cells. Local guidelines on handling of biological waste should be followed for unused medicinal product or waste material. All material that has been in contact with Kymriah (solid and liquid waste) should be handled and disposed in accordance with local guidelines on handling of biological waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Approved in Aug 2024 by EMA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>